US20060110367A1 - Compositions and methods for inhibiting pathogenic growth - Google Patents
Compositions and methods for inhibiting pathogenic growth Download PDFInfo
- Publication number
- US20060110367A1 US20060110367A1 US11/160,470 US16047005A US2006110367A1 US 20060110367 A1 US20060110367 A1 US 20060110367A1 US 16047005 A US16047005 A US 16047005A US 2006110367 A1 US2006110367 A1 US 2006110367A1
- Authority
- US
- United States
- Prior art keywords
- lactobacillus
- cfu
- day
- lactic acid
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 96
- 239000000203 mixture Substances 0.000 title claims abstract description 55
- 230000001717 pathogenic effect Effects 0.000 title claims description 54
- 230000002401 inhibitory effect Effects 0.000 title description 14
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 122
- 241001465754 Metazoa Species 0.000 claims abstract description 112
- 241000894006 Bacteria Species 0.000 claims abstract description 92
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 65
- 241001646719 Escherichia coli O157:H7 Species 0.000 claims abstract description 63
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 63
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 63
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 61
- 239000004310 lactic acid Substances 0.000 claims abstract description 61
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims abstract description 41
- 241000186428 Propionibacterium freudenreichii Species 0.000 claims abstract description 33
- 244000052769 pathogen Species 0.000 claims description 69
- 241000186660 Lactobacillus Species 0.000 claims description 68
- 229940039696 lactobacillus Drugs 0.000 claims description 68
- 241000282849 Ruminantia Species 0.000 claims description 26
- 235000013365 dairy product Nutrition 0.000 claims description 24
- 235000013305 food Nutrition 0.000 claims description 22
- 235000013336 milk Nutrition 0.000 claims description 22
- 239000008267 milk Substances 0.000 claims description 22
- 210000004080 milk Anatomy 0.000 claims description 22
- 241000588724 Escherichia coli Species 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 241000186429 Propionibacterium Species 0.000 claims description 15
- 208000015181 infectious disease Diseases 0.000 claims description 15
- 241000607142 Salmonella Species 0.000 claims description 11
- 241000186840 Lactobacillus fermentum Species 0.000 claims description 10
- 241000186839 Lactobacillus fructivorans Species 0.000 claims description 10
- 241001468191 Lactobacillus kefiri Species 0.000 claims description 10
- 241000186851 Lactobacillus mali Species 0.000 claims description 10
- 241000186612 Lactobacillus sakei Species 0.000 claims description 10
- 241000186871 Lactobacillus murinus Species 0.000 claims description 8
- 241000191967 Staphylococcus aureus Species 0.000 claims description 8
- 210000000936 intestine Anatomy 0.000 claims description 8
- 241000218492 Lactobacillus crispatus Species 0.000 claims description 7
- 230000000968 intestinal effect Effects 0.000 claims description 7
- 241000186712 Lactobacillus animalis Species 0.000 claims description 6
- 241000194017 Streptococcus Species 0.000 claims description 6
- 241000193815 Atopobium minutum Species 0.000 claims description 5
- 244000063299 Bacillus subtilis Species 0.000 claims description 5
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 5
- 241000186018 Bifidobacterium adolescentis Species 0.000 claims description 5
- 241001134770 Bifidobacterium animalis Species 0.000 claims description 5
- 241001468229 Bifidobacterium thermophilum Species 0.000 claims description 5
- 241000206593 Carnobacterium divergens Species 0.000 claims description 5
- 241000206600 Carnobacterium maltaromaticum Species 0.000 claims description 5
- 241001546092 Coprophilus Species 0.000 claims description 5
- 241001430190 Eggerthia catenaformis Species 0.000 claims description 5
- 241000194031 Enterococcus faecium Species 0.000 claims description 5
- 241000186777 Fructobacillus fructosus Species 0.000 claims description 5
- 241000186778 Kandleria vitulina Species 0.000 claims description 5
- 241000186716 Lactobacillus agilis Species 0.000 claims description 5
- 241000186715 Lactobacillus alimentarius Species 0.000 claims description 5
- 241000186714 Lactobacillus amylophilus Species 0.000 claims description 5
- 241000186713 Lactobacillus amylovorus Species 0.000 claims description 5
- 241000186723 Lactobacillus bifermentans Species 0.000 claims description 5
- 240000001929 Lactobacillus brevis Species 0.000 claims description 5
- 235000013957 Lactobacillus brevis Nutrition 0.000 claims description 5
- 244000199885 Lactobacillus bulgaricus Species 0.000 claims description 5
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 claims description 5
- 244000199866 Lactobacillus casei Species 0.000 claims description 5
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 5
- 241001468197 Lactobacillus collinoides Species 0.000 claims description 5
- 241000186842 Lactobacillus coryniformis Species 0.000 claims description 5
- 241000202367 Lactobacillus coryniformis subsp. torquens Species 0.000 claims description 5
- 241001134659 Lactobacillus curvatus Species 0.000 claims description 5
- 241000186673 Lactobacillus delbrueckii Species 0.000 claims description 5
- 241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 claims description 5
- 241000186841 Lactobacillus farciminis Species 0.000 claims description 5
- 241000186606 Lactobacillus gasseri Species 0.000 claims description 5
- 240000002605 Lactobacillus helveticus Species 0.000 claims description 5
- 235000013967 Lactobacillus helveticus Nutrition 0.000 claims description 5
- 241001147748 Lactobacillus heterohiochii Species 0.000 claims description 5
- 241000186685 Lactobacillus hilgardii Species 0.000 claims description 5
- 241001561398 Lactobacillus jensenii Species 0.000 claims description 5
- 241001134654 Lactobacillus leichmannii Species 0.000 claims description 5
- 241000520745 Lactobacillus lindneri Species 0.000 claims description 5
- 241000751214 Lactobacillus malefermentans Species 0.000 claims description 5
- 241001104724 Lactobacillus mobilis Species 0.000 claims description 5
- 241000186684 Lactobacillus pentosus Species 0.000 claims description 5
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 5
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 5
- 241000186604 Lactobacillus reuteri Species 0.000 claims description 5
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 5
- 241001438705 Lactobacillus rogosae Species 0.000 claims description 5
- 241000186870 Lactobacillus ruminis Species 0.000 claims description 5
- 241000186869 Lactobacillus salivarius Species 0.000 claims description 5
- 241000186868 Lactobacillus sanfranciscensis Species 0.000 claims description 5
- 235000013864 Lactobacillus sanfrancisco Nutrition 0.000 claims description 5
- 241000186867 Lactobacillus sharpeae Species 0.000 claims description 5
- 241000751212 Lactobacillus vaccinostercus Species 0.000 claims description 5
- 241000577554 Lactobacillus zeae Species 0.000 claims description 5
- 235000013471 Lactococcus lactis subsp hordniae Nutrition 0.000 claims description 5
- 241000194034 Lactococcus lactis subsp. cremoris Species 0.000 claims description 5
- 241001183079 Lactococcus lactis subsp. hordniae Species 0.000 claims description 5
- 241000194041 Lactococcus lactis subsp. lactis Species 0.000 claims description 5
- 241000192001 Pediococcus Species 0.000 claims description 5
- 241000191996 Pediococcus pentosaceus Species 0.000 claims description 5
- 241000186334 Propionibacterium freudenreichii subsp. shermanii Species 0.000 claims description 5
- 235000014962 Streptococcus cremoris Nutrition 0.000 claims description 5
- 235000014969 Streptococcus diacetilactis Nutrition 0.000 claims description 5
- 241000194046 Streptococcus intermedius Species 0.000 claims description 5
- 244000057717 Streptococcus lactis Species 0.000 claims description 5
- 235000014897 Streptococcus lactis Nutrition 0.000 claims description 5
- 241000186675 Weissella confusa Species 0.000 claims description 5
- 241000186838 Weissella halotolerans Species 0.000 claims description 5
- 241000186837 Weissella kandleri Species 0.000 claims description 5
- 241000186864 Weissella minor Species 0.000 claims description 5
- 241000186882 Weissella viridescens Species 0.000 claims description 5
- 229940118852 bifidobacterium animalis Drugs 0.000 claims description 5
- 229940068140 lactobacillus bifidus Drugs 0.000 claims description 5
- 229940004208 lactobacillus bulgaricus Drugs 0.000 claims description 5
- 229940017800 lactobacillus casei Drugs 0.000 claims description 5
- 229940012969 lactobacillus fermentum Drugs 0.000 claims description 5
- 229940054346 lactobacillus helveticus Drugs 0.000 claims description 5
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 5
- 229940001882 lactobacillus reuteri Drugs 0.000 claims description 5
- 241000186425 Acidipropionibacterium jensenii Species 0.000 claims description 4
- 241000186000 Bifidobacterium Species 0.000 claims description 4
- 241001608472 Bifidobacterium longum Species 0.000 claims description 4
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims description 4
- 241000192013 Peptoniphilus asaccharolyticus Species 0.000 claims description 4
- 241000605031 Selenomonas ruminantium Species 0.000 claims description 4
- 241000194020 Streptococcus thermophilus Species 0.000 claims description 4
- 229940004120 bifidobacterium infantis Drugs 0.000 claims description 4
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 4
- 230000008030 elimination Effects 0.000 claims description 2
- 238000003379 elimination reaction Methods 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 29
- 239000006041 probiotic Substances 0.000 abstract description 9
- 235000018291 probiotics Nutrition 0.000 abstract description 9
- 244000052616 bacterial pathogen Species 0.000 abstract description 8
- 230000000529 probiotic effect Effects 0.000 abstract description 7
- 244000005700 microbiome Species 0.000 description 36
- 241000283690 Bos taurus Species 0.000 description 32
- 238000009472 formulation Methods 0.000 description 17
- 238000012360 testing method Methods 0.000 description 15
- 244000309466 calf Species 0.000 description 14
- 235000015278 beef Nutrition 0.000 description 11
- 230000002550 fecal effect Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 230000009467 reduction Effects 0.000 description 10
- 240000008042 Zea mays Species 0.000 description 8
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 8
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 8
- 235000005822 corn Nutrition 0.000 description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 description 8
- 238000011081 inoculation Methods 0.000 description 8
- 235000013372 meat Nutrition 0.000 description 8
- 230000009471 action Effects 0.000 description 7
- 235000005911 diet Nutrition 0.000 description 7
- 230000037213 diet Effects 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 210000004767 rumen Anatomy 0.000 description 6
- 238000003307 slaughter Methods 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 235000013877 carbamide Nutrition 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 241000194033 Enterococcus Species 0.000 description 3
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 235000021243 milk fat Nutrition 0.000 description 3
- 230000017066 negative regulation of growth Effects 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 240000004658 Medicago sativa Species 0.000 description 2
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 2
- 102000014171 Milk Proteins Human genes 0.000 description 2
- 108010011756 Milk Proteins Proteins 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 description 2
- 235000021052 average daily weight gain Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000004464 cereal grain Substances 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 235000021045 dietary change Nutrition 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 235000021050 feed intake Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 235000021239 milk protein Nutrition 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- GAOZTHIDHYLHMS-KEOBGNEYSA-N monensin A Chemical compound C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-KEOBGNEYSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000020185 raw untreated milk Nutrition 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000006152 selective media Substances 0.000 description 2
- 239000004460 silage Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 229940007392 tylan Drugs 0.000 description 2
- WBPYTXDJUQJLPQ-VMXQISHHSA-N tylosin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 WBPYTXDJUQJLPQ-VMXQISHHSA-N 0.000 description 2
- 235000019375 tylosin Nutrition 0.000 description 2
- BDVFVCGFMNCYPV-UHFFFAOYSA-N 5-(2-methylpiperazine-1-sulfonyl)isoquinoline Chemical compound CC1CNCCN1S(=O)(=O)C1=CC=CC2=CN=CC=C12 BDVFVCGFMNCYPV-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 108010062877 Bacteriocins Proteins 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 240000001817 Cereus hexagonus Species 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 206010014896 Enterocolitis haemorrhagic Diseases 0.000 description 1
- 241001333951 Escherichia coli O157 Species 0.000 description 1
- 101100232738 Gallus gallus IFNL3 gene Proteins 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 235000003228 Lactuca sativa Nutrition 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108010017898 Shiga Toxins Proteins 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000019730 animal feed additive Nutrition 0.000 description 1
- 239000012805 animal sample Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000369 enteropathogenic effect Effects 0.000 description 1
- 210000003013 erythroid precursor cell Anatomy 0.000 description 1
- 230000003636 fecal output Effects 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 244000078673 foodborn pathogen Species 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000010871 livestock manure Substances 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 238000012794 pre-harvesting Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940007046 shigella dysenteriae Drugs 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/853—Lactobacillus
- Y10S435/854—Lactobacillus acidophilus
Definitions
- the present invention relates to compositions and methods for inhibiting pathogenic growth. More specifically, the invention relates to compositions and methods for inhibiting pathogenic growth through the use of lactic acid producing microorganisms both alone and in combination with lactate utilizing microorganisms.
- pathogens especially bacterial pathogens, but including viruses and other disease causing microorganisms
- Pathogens have been known to cause illnesses in animals that have wide ranging deleterious effects including weight loss, diarrhea, abdominal cramping, and renal failure. For animals that are immunosuppressed or malnourished, even just the effects of diarrhea can be fatal. Pathogens are often transferred between animals where poor hygiene conditions exist, and sometimes communicability cannot be prevented even when great care is taken.
- the most common solution to this problem has been to provide antibiotics to the animals; however, this solution is not only costly, but it also can result in the generation of antibiotic-resistant strains of bacteria.
- enteropathogens that cause disease in the intestinal tract are known as enteropathogens.
- enteropathogenic bacteria include Staphylococcus aureus , particular strains of Escherichia coli ( E. coli ), and Salmonella spp.
- E. coli Escherichia coli
- Salmonella spp Salmonella spp.
- E. coli O157:H7, O111:H8, and O104:H21 produce large quantities of powerful shiga-like toxins that are closely related to or identical to the toxin produced by Shigella dysenteriae .
- E. coli O157:H7 can also cause acute hemorrhagic colitis, characterized by severe abdominal cramping and abdominal bleeding. In children, this can progress into the rare but fatal disorder called hemolytic uremic syndrome (“HUS”), characterized by renal failure and hemolytic anemia. In adults, it can progress into an ailment termed thrombotic thrombocytopenic purpura (“TTP”), which includes HUS plus fever and neurological symptoms and can have a mortality rate as high as fifty percent in the elderly.
- HUS hemolytic uremic syndrome
- TTP thrombotic thrombocytopenic purpura
- enteropathogens such as E. coli O157:H7 for the health benefits to the animals.
- enteropathogens such as E. coli O157:H7
- enteropathogens in meat and milk producing animals prior to their harvest for the benefit of consumers.
- pathogens are known to populate many distinct areas of animals' digestive tracts, it has been found to be most beneficial to supply and potentiate those organisms that occur naturally in those areas and which are effective for inhibiting pathogenic growth throughout the digestive tract, such as the rumen, small intestine, and large intestine.
- the present invention identifies such naturally occurring organisms suitable for serving this purpose and demonstrates methods for enhancing their populations and efficacy.
- the microorganisms in the formulations and methods of the present inventions may individually and collectively produce compounds that inhibit the growth of pathogens in the gastrointestinal tract (“GIT”) of animals. By inhibiting the growth of the pathogens, the methods and compounds of the invention provide a reduced likelihood of contaminated food products resulting from treated animals.
- GIT gastrointestinal tract
- the invention exploits the natural competition of certain microorganisms with the pathogenic organisms that it is the object of the invention to reduce or destroy.
- the microorganisms in the formulations of the invention may exhibit multifaceted modes of action. These actions range from complex actions such as acting as or producing bactericides to simply competing with the pathogen by using more nutrients and attachment spaces than the pathogens, thus preventing them from becoming established within the GIT. These advantageous action modes can be contrasted with less advantageous techniques conventionally known for achieving such effects as using aseptic husbandry accompanied by the addition of antibiotics and like substances to animals' feed.
- E. coli O157:H7 and Lactobacillus acidophilus are understood to at least partly utilize the same limited supply of in vitro nutrients such as sugar. Furthermore, these microorganisms compete for the same attachment space: on the lining of the GIT. With a rapid-proliferation inhibitor such as Lactobacillus acidophilus , the primary mode of action against E. coli O157:H7 is to overwhelm it by using the available food and suitable attachment spaces.
- the invention includes a method of treating or preventing an intestinal pathogenic infection in a ruminant comprising administering to the ruminant a composition comprising a therapeutically effective amount of a lactic acid producing bacterium, wherein the lactic acid producing bacterium reduces the quantity of a pathogen in the intestine of the ruminant.
- the lactic acid producing bacterium is selected from the group consisting of: Bacillus subtilis, Bifidobacterium adolescentis, Bifidobacterium animalis, Bifidobacterium bifudum, Bifidobacterium infantis, Bifidobacterium longum, Bifidobacterium thermophilum, Lactobacillus acidophilus, Lactobacillus agilis, Lactobacillus alactosus, Lactobacillus alimentarius, Lactobacillus amylophilus, Lactobacillus amylovorans, Lactobacillus amylovorus, Lactobacillus animalis, Lactobacillus batatas, Lactobacillus bavaricus, Lactobacillus bifermentans, Lactobacillus bifidus, Lactobacillus brevis, Lactobacillus buchnerii, Lactobacillus bulgaricus, Lactobacillus catena
- the lactic acid producing bacterium is Lactobacillus acidophilus .
- the Lactobacillus acidophilus strains include the M35, LA45, LA51 and L411 strains.
- the Lactobacillus acidophilus strain is LA51.
- the lactic acid producing bacterium may be administered at a level of at least 1 ⁇ 10 8 CFU/day. Alternatively, the lactic acid producing bacterium may be administered at a level of about 1 ⁇ 10 9 CFU/day.
- the pathogen may be selected from the group consisting of E. coli, Salmonella spp., including Salmonella typhirium , and Staphylococcus aureus . Alternatively, the pathogen may be E. coli O157:H7.
- Another aspect of the invention includes a composition for treating or preventing a pathogenic infection in a ruminant comprising a Lactobacillus acidophilus strain selected from the group consisting of M35, LA45, LA51 and L411 in combination with animal feed.
- a Lactobacillus acidophilus strain selected from the group consisting of M35, LA45, LA51 and L411 in combination with animal feed.
- the Lactobacillus acidophilus strain is LA45 or LA51.
- the Lactobacillus acidophilus strain is LA51.
- the Lactobacillus acidophilus may be present in the animal feed in an amount of greater than 1 ⁇ 10 8 CFU for each quantity of food equal to the amount eaten by one animal in one day, or the Lactobacillus acidophilus may be present in the animal feed in an amount of about 1 ⁇ 10 9 CFU for each quantity of food equal to the amount eaten by one animal in one day.
- strain LA51 is also known as 381-IL-28, and is available under that accession number from the Oklahoma State University collection. While the inventors have characterized LA51 as a Lactobacillus acidophilus , other means of characterization have identified it as Lactobacillus animalis , and Lactobacillus murinus .
- LA45 is deposited at the American Type Culture Collection under accession number ATCC 53545. M35 and L411 are the accession numbers for those bacteria available from the University of Kansas.
- Another aspect of the invention includes a method of treating or preventing an intestinal pathogenic infection in a ruminant, the method comprising administering to the ruminant a composition comprising a therapeutically effective amount of a lactic acid producing bacterium and a lactate utilizing bacterium, wherein the lactic acid producing bacterium reduces the quantity of a pathogen in the intestine of the ruminant.
- the lactic acid producing bacterium may be selected from the group consisting of: Bacillus subtilis, Bifidobacterium adolescentis, Bifidobacterium animalis, Bifidobacterium bifudum, Bifidobacterium infantis, Bifidobacterium longum, Bifidobacterium thermophilum, Lactobacillus acidophilus, Lactobacillus agilis, Lactobacillus alactosus, Lactobacillus alimentarius, Lactobacillus amylophilus, Lactobacillus amylovorans, Lactobacillus amylovorus, Lactobacillus animalis, Lactobacillus batatas, Lactobacillus bavaricus, Lactobacillus bifermentans, Lactobacillus bifidus, Lactobacillus brevis, Lactobacillus buchnerii, Lactobacillus bulgaricus, Lactobacillus catenaforme
- the lactate utilizing bacterium may be selected from the group consisting of Megasphaerae eilsdenii, Peptostreptococcus asaccharolyticus, Propionibacterium freudenreichii, Propionibacterium acid-propionici, Propionibacterium freudenreichii, Propionibacterium globosum, Propionibacterium jensenii, Propionibacterium shermanii, Propionibacterium spp., Selenomonas ruminantium , and combinations thereof.
- the lactic acid producing bacterium is Lactobacillus acidophilus .
- the Lactobacillus acidophilus strain is selected from the group consisting of M35, LA45, LA51 and L411. In another embodiment, the Lactobacillus acidophilus is the LA51 strain.
- the lactate utilizing bacterium is Propionibacterium freudenreichii . In another embodiment, the Propionibacterium freudenheimii strain is selected from the group consisting of P9, PF24, P42, P93 and P99. In another embodiment, the Propionibacterium freudenheimii strain is PF24, available from the ATCC under accession number ATCC 9615.
- the lactate utilizing bacterium and the lactic acid producing bacterium may each be administered in an amount of greater than 1 ⁇ 10 8 CFU/day, or in an amount of about 1 ⁇ 10 9 CFU/day.
- the lactate utilizing bacterium may be administered in an amount of about 1 ⁇ 10 6 CFU/day.
- the lactate utilizing bacterium is administered in an amount of greater than 1 ⁇ 10 6 CFU/day, preferably in an amount of greater than 1 ⁇ 10 8 CFU/day, and most preferably in an amount of about 1 ⁇ 10 9 CFU/day.
- compositions for treating or preventing a pathogenic infection in a ruminant comprising a Lactobacillus acidophilus strain selected from the group consisting of M35, LA45, LA51, L411, and combinations thereof, in combination with a Propionibacterium freudenreichii strain selected from the group consisting of P9, PF24, P42, P93, P99, and combinations thereof.
- the composition further comprises animal feed.
- the Lactobacillus acidophilus and the Propionibacterium freudenreichii are each present in the animal feed in an amount of greater than 1 ⁇ 10 8 CFU for each quantity of food equal to the amount eaten by one animal in one day.
- the Lactobacillus acidophilus strain LA51 and Propionibacterium freudenreichii strain PF24 are each present in the animal feed in an amount of about 1 ⁇ 10 9 CFU for each quantity of food equal to the amount eaten by one animal in one day.
- the composition further comprises Lactobacillus acidophilus strain LA45 present in the animal feed in an amount of about 1 ⁇ 10 6 CFU for each quantity of food equal to the amount eaten by one animal in one day.
- the present invention provides methods and compositions for reducing or eliminating the growth of pathogens in the gut of an animal.
- In vitroand in vivotests have been conducted utilizing certain strains of microorganisms, which have been found to be particularly effective at inhibiting the growth of many pathogens, including E. coli O157:H7.
- pathogens refers to any bacterium that produces a harmful effect in a host animal, and especially those bacteria that infect meat and dairy animals and subsequently infect the human food supply, thus causing disease in humans.
- the invention is considered to be useful in preventing the growth of a wide variety of pathogenic organisms, as demonstrated herein by several tests showing the inhibition of growth of pathogenic bacteria including E. coli, Salmonella spp., including Salmonella typhirium , and Staphylococcus aureus.
- the formulations and methods described herein are applicable to a wide variety of animal species and commercial practices.
- the inhibition of pathogens in the GIT of animals may be considered for those used in the commercial production of meat, milk, poultry, and fish.
- the invention includes a method for treating an animal to inhibit the incidence and growth of E. coli O157:H7.
- the treatment method includes administering a therapeutically effective amount of a selected Lactobacillus acidophilus to an animal that inhibits in vivo growth of E. coli O157:H7.
- the term “therapeutically effective amount” refers to the quantity of bacteria administered to an animal that results in a therapeutic effect by creating an inhospitable environment for pathogens.
- a therapeutically effective amount of Lactobacillus acidophilus can be as little as 1 ⁇ 10 6 CFU/day when it is administered in combination with other components, although it is preferable that the lactic acid producing bacteria of the invention are administered in an amount of greater than 1 ⁇ 10 8 CFU/day. It has been found to be particularly effective when the selected Lactobacillus acidophilus is administered at a level of approximately 1 ⁇ 10 9 CFU/day.
- the invention includes Lactobacillus acidophilus strains that are effective compositions in the above-described methods when provided as a product in the prescribed concentrations for animal consumption as E. coli O157:H7 inhibitors.
- Lactobacillus acidophilus microorganisms had been administered as animal feed additives for different purposes such as better utilization of feed-stuffs. For example, U.S. Pat. Nos.
- the present invention includes a method for providing a product as an inhibitor of E. coli O157:H7 growth in animals.
- the method includes selecting a therapeutically effective microorganism as an E. coli O157:H7 inhibitor in animals and producing a product containing this microorganism.
- such products require government approval to be certified as pathogen inhibitors; specifically, certification from the United States Department of Agriculture (USDA) is typically required.
- USDA United States Department of Agriculture
- FDA United States Food and Drug Administration
- An example of a microorganism found to be therapeutically effective is Lactobacillus acidophilus , preferably the LA51 strain, which inhibits in vivo growth of E. coli O157:H7 and other pathogenic microorganisms when administered to animals at a dose of approximately 1 ⁇ 10 9 CFU/day. Alternatively, a sufficient level may be considered to be at least as much as 1 ⁇ 10 8 CFU/day. Exact dosage levels can easily be determined by those skilled in the art by evaluating the bile tolerance of the bacteria to be administered in order to verify that viable organisms are delivered to the intestinal tract to compete with and inhibit the growth of pathogenic bacteria such as E. coli O157:H7.
- the present invention identifies several naturally occurring organisms that are capable of inhibiting pathogen growth within the GIT of an animal. Since many pathogens are acid resistant and populate many distinct areas of an animal's digestive tract, the naturally occurring organisms of the invention are preferably capable of inhibiting pathogen growth at a lower pH and in several areas of the GIT; e.g., the rumen, small intestine and large intestine.
- E. coli O157:H7 populations may be decreased in cattle by feeding hay rations, which in and of itself increases rumen pH to 7.0.
- this has limited application in the finishing or feedlot industries since animals in this phase of the production process are typically fed a diet that has a greater proportion of grain in order to foster better carcass characteristics.
- Microorganisms that are useful in the formulations and methods of the present invention may be capable of producing lactic acid in the GIT.
- These microorganisms include, for example, the genera Lactobacillus or Enterococcus . Either or both genera may be used. They are distinguished by their ability to utilize sugars such as glucose or lactose or, in the case of Enterococcus , to utilize starch, to produce lactic acid, and thus reduce the local pH level.
- the choice of microorganism can depend upon the locus at which the desired effect is to be given. For example, the genus Lactobacillus is capable of reducing local pH more than Enterococcus microorganisms.
- Lactic acid producing organisms that may be used in the methods and compositions of the invention include but are not limited to: Bacillus subtilis, Bifidobacterium adolescentis, Bifidobacterium animalis, Bifidobacterlum bifudum, Bifidobacterlum infantis, Bifidobacterlum longum, Bifidobacterium thermophilum, Lactobacillus acidophilus, Lactobacillus agilis, Lactobacillus alactosus, Lactobacillus alimentarius, Lactobacillus amylophilus, Lactobacillus amylovorans, Lactobacillus amylovorus, Lactobacillus animalis, Lactobacillus batatas, Lactobacillus bavaricus, Lactobacillus bifermentans, Lactobacillus bifidus, Lactobacillus brevis, Lactobacillus buchnerii, Lactobacillus bulgaricus, Lacto
- any of the above listed lactic acid producing microorganisms may be used to inhibit or treat infections of a host of pathogens, particularly bacterial pathogens including pathogenic bacteria such as Escherichia coli, Staphylococcus aureus , and Salmonella spp., including Salmonella typhirium .
- pathogens particularly bacterial pathogens including pathogenic bacteria such as Escherichia coli, Staphylococcus aureus , and Salmonella spp., including Salmonella typhirium .
- pathogenic bacteria such as Escherichia coli, Staphylococcus aureus , and Salmonella spp., including Salmonella typhirium .
- Salmonella typhirium Salmonella typhirium
- These lactic acid producing microorganisms are particularly useful for inhibiting or treating infections of E. coli O157:H7. It has also been found that these organisms may be used for improving the performance of food animals by increasing carcass weight, carcass quality, reducing carcass
- the invention includes a formulation of a combination of lactic acid producing microorganisms, such as those described in the preceding paragraphs, with a second microorganism that enhances the effectiveness of the lactic acid producing microorganisms in competing with pathogenic microorganisms.
- Enhancing microorganisms that may be used in the formulations of the present invention are preferably lactate utilizing microoorganisms.
- lactate utilizing microorganisms useful in the present invention include but are not limited to: Megasphaerae eilsdenii, Peptostreptococcus asaccharolyticus, Propionibacterium freudenreichii, Propionibacterium acid - propionici, Propionibacterium freudenreichii, Propionibacterium globosum, Propionibacterium jensenii, Propionibacterium shermanii, Propionibacterium spp., and Selenomonas ruminantium .
- a therapeutically effective amount of these enhancing microorganisms is a quantity that produces a beneficial therapeutic effect in the animal to which they are administered, for example, a therapeutically effective amount of these enhancing microorganisms may be greater than 1 ⁇ 10 6 CFU/day, preferably 1 ⁇ 10 8 CFU/day, or even more preferably about 1 ⁇ 10 9 CFU/day.
- microorganisms ensures that the desired effect is produced locally.
- the different microorganisms used in the formulation should be compatible with each other, for example, capable of growing together, and preferably, potentiating the other. Additionally, the microorganisms preferably grow fast at the locus of action.
- the microorganisms may be selected for various characteristics, such as resistance to bile acids and/or commercial antibiotics, that make them most suited for their intended use.
- the formulations of the invention include Lactobacillus acidophilus, Lactobacillus crispatus , or Lactobacillus murinus , either individually or in any combination.
- the formulations of the invention include Lactobacillus acidophilus, Lactobacillus crispatus , or Lactobacillus murinus , either individually or in any combination with each other, and additionally include Propionibacterium freudenreichii or Propionibacterium shermanii or both.
- the formulations of the invention are applied to the daily feed of beef or dairy cattle in a dry supplement, or in a liquid spray applied to the daily feed of the animals.
- the formulations may be administered once a day or over the course of a day, either in one meal, or divided among the meals, or in any other suitable way.
- Lyophilized cultures of lactic acid producing and lactate utilizing organisms were selected for their ability to inhibit the growth of pathogens such as E. coli O157:H7, Streptococcus aureus and Salmonella . Combinations of the lactic acid producing and lactate utilizing organisms were further selected for their ability to maximize the inhibition of growth of the various pathogens.
- ruminants were inoculated by providing a sufficient quantity of the bacterial strains tested along with necessary growth medium components to the ruminants' intestines by normal ingestion. Inhibited growth of pathogens such as E. coli O157:H7 were observed in feedlot and dairy cattle, as well as other ruminants such as sheep, goats and game.
- pathogens such as E. coli O157:H7
- ruminants such as sheep, goats and game.
- Various inoculation processes were utilized. Examples of these inoculation processes include:
- the mixture can be in dry form, together with additional carriers that are added to the diet of the animal.
- the diet can include one or more ingredients such as corn, cereal grains, corn byproducts, cereal grain byproducts, alfalfa hay, corn silage, small grain silage, grass hay, plant stalks, oilseed byproducts, protein meals, urea, minerals, molasses, and various fat and oil products.
- the data is reported at log 10 CFU E. coli O157:H7/ml.
- the organisms PF24, LA45 and LA51 are all able to function at a pH of about 4.0 to about 5.0 up to above a pH of about 7.0.
- the chief concern is inhibiting pathogens of cattle on a finishing diet containing high levels of concentrate that tend to decrease rumen pH from about 7.0 to the range of about 5.0 to about 6.9, a range in which the formulation of the present invention preferably functions.
- M35 and LA51 each demonstrate the ability to inhibit shedding of E. coli O157:H7 by about fifty percent above the level of the control animals.
- NPC 747 and NPC 750 Two separate treatments utilizing two separate types of lactic acid producing bacteria (NPC 747 and NPC 750) were administered to test their ability to reduce E. coli O157:H7 in the study animals.
- Pen tests taken one week following the beginning of the treatment period indicated that 25% of the pens receiving no treatment were positive for E. coli O157:H7, while 8% of the pens receiving NPC 750 treatment were positive and 0% of the pens receiving NPC 747 treatment were positive.
- 50% of the samples taken from the control (untreated) animals were positive, while only 30% and 20% of the samples from animals receiving NPC 750 and NPC 747 treatments, respectively, were positive for E. coli O157:H7.
- the tests indicate a reduction in the shedding rate by approximately one-half that of the control for those receiving NPC 747 treatment, which was a greater reduction than for those receiving NPC 750 treatment. All animals shedding E.
- the animals were sampled pre-slaughter.
- the animals receiving NPC 747 treatment had significantly (P ⁇ 0.05) less detectable E. coli O157:H7 with only 3.3% of the animals testing positive.
- the animals receiving the NPC 750 strain and those in the control group were not significantly different, with 15% and 20% shedding, respectively.
- Fecal samples taken in the slaughter plant indicated that 3.3% of the NPC 747 treated animals were positive, 6.6% of the NPC 750 treated animals were positive, and 1 0% of the control animals were positive. Averaging all samples over all sampling times, 61.7% of the control animals shed the pathogen during the feeding period, 51.7% of the NPC 750 animals shed the pathogen, and only 35% of the NPC 747 treated animals shed the pathogen.
- probiotic bacteria in the study included various bovine fecal Lactobacillus spp. isolates that were selected on the basis of high-level in vitro toxic activity against E. coli O157:H7.
- the calves were challenged by intra-ruminal inoculation with E. coli O157:H7 (C1). Fifteen (C2) and twenty seven (C3) days after the first inoculation (C1), the calves were again challenged.
- the first inoculation C1 comprised a total of about 1 ⁇ 10 9 CFU of a combination of strains 920, 922, 944 and 966.
- the second inoculation C2 was with a total of about 1.63 ⁇ 10 11 CFU of these strains.
- the third inoculation C3 included about 1 ⁇ 10 9 CFU of strain 86-24.
- the shedding/challenge ratio in the above table represents the total amount of E. coli O157:H7 shed after inoculation. This number normalizes the values allowing more accurate comparison of the animals and providing more meaningful information than just reviewing the total number of days the cattle shed the organism.
- M35, LA45, LA51 and L411 represent the various Lactobacillus strains tested.
- PBS represents the control animal.
- the total shedding is the CFU per gram in feces times the fecal output in grams on a positive day of shedding times the total number of positive days of shedding.
- the third set of dairy cows were administered the lactate utilizing bacterium Propionibacterium freudenreichii strain PF24 in combination with two stains of the lactic acid producing bacterium Lactobaciullus acidophilus , LA51 (NPC747) and LA45, in accordance with the methods set forth in the preceding sections (Group 3). The results of this study are set forth in table 9.
- Table 9 demonstrates the effects of each of the treatment regimes on the milk production, body weight, and feed consumption of the dairy cows.
- the data demonstrates that treatments involving feeding the dairy cows lactate utilizing bacteria in combination with lactic acid producing bacteria resulted in statistically significant improvements in the quantity of milk produced, the quantity of fat corrected milk produced (i.e., milk with a higher fat content is weighted more), the ratio of fat corrected milk produced per quantity of feed consumed, the quantity of energy corrected milk produced (i.e., milk with a higher calorie content is weighted more), the quantity of energy corrected milk produced per quantity of feed consumed, the quantity of milk fat in the milk produced, and the urea content of the cows' blood serum.
- Table 10 shows a marked reduction in the occurrence of the pathogen E. coli O157:H7 in fecal samples from each of the sets of dairy cows to which the combination of lactate utilizing bacteria and lactic acid producing bacteria were administered. The effect was particularly pronounced in the dairy cows administered both the LA51 (NPC747) and LA45 strains of L. acidophilus in combination with the PF24 strain of P. freudenheimii . In this set of cows, no E. coli O157:H7 was detected in any fecal samples. TABLE 10 Occurrence of E. coli O157:H7 in Fecal Samples from Dairy Cows Group 1 Group 2 Group 3 E. coli O157:H7 19% 12% 0% occurrence
- Each pen was allotted one of four treatments: (1) group 1 was the control group and was fed no microorganisms, (2) group 2 was fed two strains: Propionibacterium freudenreichii strain PF24 and Lactobacillus acidophilus strain LA51 (NPC747), each strain in an amount of 1 ⁇ 10 9 CFU/day, (3) group 3 was fed three strains: PF24 in an amount of 1 ⁇ 10 9 CFU/day, LA51 (NPC747) in an amount of 1 ⁇ 10 9 CFU/day, and Lactobacillus acidophilus strain LA45 in an amount of 1 ⁇ 10 6 CFU/day, and (4) group 4 was fed three strains: PF24 in an amount of 1 ⁇ 10 9 CFU/day, LA51 (NPC747) in an amount of 1 ⁇ 10 6 CFU/day, and Lactobacillus acidophilus strain LA45 in an amount of 1 ⁇ 10 6 CFU/day.
- Table 11 demonstrates an improvement in the feeding efficiencies of the groups administered the novel combinations of bacteria. All of the groups administered the novel combinations of bacteria exhibited a greater average daily weight gain over the course of 56 and 1 40 days relative to the control group.
- Table 12 demonstrates a substantial improvement in the quantity of E. coli O157:H7 found in the carcasses and hides of the steers following slaughter. Notably, the carcasses of the steers in Group 2 exhibited less than half of this pathogen than the control group, and the carcasses of the steers in the other two groups also exhibited a substantial reduction in the quantity of this pathogen. Particularly notable is the dramatic reduction in the quantity of E. coli in the hides of all of the steers who were administered the formulations of the invention. TABLE 12 E. coli O157:H7 incidence Carcass Hide Group 1 (control) 33.3% 20% Group 2 13.3% 0% Group 3 26.6% 0% Group 4 20% 0%
- the first method involved feeding the bacteria NPC 747 and NPC 750 (also known as M35, available under that name from the University of Kansas) to cattle.
- the second method involved removing starch from the cattle's diet.
- the third method involved pen cleaning.
- the study design was 3 H 2 H 2 factorial.
- a finishing diet (33% high moisture corn, 20% dry rolled corn, 40% wet corn gluten feed, and 7% alfalfa, with vitamins, minerals, Rumensin, and Tylan) was fed to 432 steers (average weight 340 kg) in 54 pens, with 8 steers in each pen.
- the bacteria NPC 747 and NPC 750 was fed daily to the cattle in 1 8 pens. Half the pens were cleaned monthly, and the other half were cleaned only at the end of the study. Two weeks prior to slaughter, the diet was changed for half the cattle, with corn bran replacing corn in the cattle's feed.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Animal Husbandry (AREA)
- Biomedical Technology (AREA)
- Birds (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Physiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Fodder In General (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
- This application is a Divisional Application of U.S. patent application Ser. No. 10/288,487 filed Nov. 6, 2002. Said application Ser. No. 10/288,487 is a Continuation Application of U.S. patent application Ser. No. 10/273,141 filed Oct. 18, 2002. Further, said application Ser. No. 10/288,487 claims priority to U.S. Provisional Patent Application Nos. 60/319,054 filed Jan. 8, 2002 and 60/319,587 filed Oct. 1, 2002, all applications incorporated herein by reference in their entireties.
- The present invention relates to compositions and methods for inhibiting pathogenic growth. More specifically, the invention relates to compositions and methods for inhibiting pathogenic growth through the use of lactic acid producing microorganisms both alone and in combination with lactate utilizing microorganisms.
- Ingestion of pathogens, especially bacterial pathogens, but including viruses and other disease causing microorganisms, is a common problem in most animals. Pathogens have been known to cause illnesses in animals that have wide ranging deleterious effects including weight loss, diarrhea, abdominal cramping, and renal failure. For animals that are immunosuppressed or malnourished, even just the effects of diarrhea can be fatal. Pathogens are often transferred between animals where poor hygiene conditions exist, and sometimes communicability cannot be prevented even when great care is taken. The most common solution to this problem has been to provide antibiotics to the animals; however, this solution is not only costly, but it also can result in the generation of antibiotic-resistant strains of bacteria.
- Extreme health risks result when humans consume pathogens in contaminated food products such as sprouts, lettuce, meat products, unpasteurized milk and juice, and sewage-contaminated water, for example. The problem is particularly prevalent in the beef and dairy industry. Pathogens present on a cow's udder or on milking equipment may find their way into raw milk. Meat can become contaminated during slaughter, and pathogenic organisms can be mixed into large quantities of meat when it is ground. When humans eat meat, especially ground beef, that has not been cooked sufficiently to kill any pathogens present in the beef, serious and life-threatening infections can result. This is a difficult problem to solve because contaminated meat often looks and smells perfectly normal. Furthermore, the number of pathogenic organisms needed to cause disease is extremely small, thus making detection extraordinarily difficult.
- Pathogens that cause disease in the intestinal tract are known as enteropathogens. Examples of enteropathogenic bacteria, or enterobacteria, include Staphylococcus aureus, particular strains of Escherichia coli (E. coli), and Salmonella spp. Whereas most of the hundreds of strains of E. coli are harmless and live in the intestines of animals, including humans, some strains, such as E. coli O157:H7, O111:H8, and O104:H21, produce large quantities of powerful shiga-like toxins that are closely related to or identical to the toxin produced by Shigella dysenteriae. These toxins can cause severe distress in the small intestine, often resulting in damage to the intestinal lining and resulting in extreme cases of diarrhea. E. coli O157:H7 can also cause acute hemorrhagic colitis, characterized by severe abdominal cramping and abdominal bleeding. In children, this can progress into the rare but fatal disorder called hemolytic uremic syndrome (“HUS”), characterized by renal failure and hemolytic anemia. In adults, it can progress into an ailment termed thrombotic thrombocytopenic purpura (“TTP”), which includes HUS plus fever and neurological symptoms and can have a mortality rate as high as fifty percent in the elderly.
- Reduction of risk for illnesses due to food borne pathogens can be achieved by controlling points of potential contamination. The beef industry has recognized the need to investigate pre-harvest control of pathogens, particularly E. coli O157:H7, due to potential runoff contamination, contact with humans, and the transfer of pathogens during meat processing. In particular, undercooked or raw hamburger (ground beef) has been implicated in many documented outbreaks as containing E. coli O157:H7.
- Accordingly, there is a recognized need for compositions and methods for reducing or eliminating the growth of enteropathogens such as E. coli O157:H7 for the health benefits to the animals. Furthermore, there is an important need for reducing or eliminating the growth of enteropathogens in meat and milk producing animals prior to their harvest for the benefit of consumers. By such reduction or elimination in food animals, consumers of beef, dairy, and other food products will be better protected from the risk of consuming such pathogens.
- Since pathogens are known to populate many distinct areas of animals' digestive tracts, it has been found to be most beneficial to supply and potentiate those organisms that occur naturally in those areas and which are effective for inhibiting pathogenic growth throughout the digestive tract, such as the rumen, small intestine, and large intestine. The present invention identifies such naturally occurring organisms suitable for serving this purpose and demonstrates methods for enhancing their populations and efficacy. The microorganisms in the formulations and methods of the present inventions may individually and collectively produce compounds that inhibit the growth of pathogens in the gastrointestinal tract (“GIT”) of animals. By inhibiting the growth of the pathogens, the methods and compounds of the invention provide a reduced likelihood of contaminated food products resulting from treated animals.
- The invention exploits the natural competition of certain microorganisms with the pathogenic organisms that it is the object of the invention to reduce or destroy. The microorganisms in the formulations of the invention may exhibit multifaceted modes of action. These actions range from complex actions such as acting as or producing bactericides to simply competing with the pathogen by using more nutrients and attachment spaces than the pathogens, thus preventing them from becoming established within the GIT. These advantageous action modes can be contrasted with less advantageous techniques conventionally known for achieving such effects as using aseptic husbandry accompanied by the addition of antibiotics and like substances to animals' feed.
- In the competitive mode of action, particularly of Lactobacillus acidophilus, including strain 381-IL-28 (also known as and referred to throughout as the LA51 strain and NPC747), the microorganisms out-grow and out-populate E. coli O157:H7, thereby acting as an inhibitor to that pathogen. E. coli O157:H7 and Lactobacillus acidophilus are understood to at least partly utilize the same limited supply of in vitro nutrients such as sugar. Furthermore, these microorganisms compete for the same attachment space: on the lining of the GIT. With a rapid-proliferation inhibitor such as Lactobacillus acidophilus, the primary mode of action against E. coli O157:H7 is to overwhelm it by using the available food and suitable attachment spaces.
- The invention includes a method of treating or preventing an intestinal pathogenic infection in a ruminant comprising administering to the ruminant a composition comprising a therapeutically effective amount of a lactic acid producing bacterium, wherein the lactic acid producing bacterium reduces the quantity of a pathogen in the intestine of the ruminant. In one embodiment, the lactic acid producing bacterium is selected from the group consisting of: Bacillus subtilis, Bifidobacterium adolescentis, Bifidobacterium animalis, Bifidobacterium bifudum, Bifidobacterium infantis, Bifidobacterium longum, Bifidobacterium thermophilum, Lactobacillus acidophilus, Lactobacillus agilis, Lactobacillus alactosus, Lactobacillus alimentarius, Lactobacillus amylophilus, Lactobacillus amylovorans, Lactobacillus amylovorus, Lactobacillus animalis, Lactobacillus batatas, Lactobacillus bavaricus, Lactobacillus bifermentans, Lactobacillus bifidus, Lactobacillus brevis, Lactobacillus buchnerii, Lactobacillus bulgaricus, Lactobacillus catenaforme, Lactobacillus casei, Lactobacillus cellobiosus, Lactobacillus collinoides, Lactobacillus confusus, Lactobacillus coprophilus, Lactobacillus coryniformis, Lactobacillus corynoides, Lactobacillus crispatus, Lactobacillus curvatus, Lactobacillus delbrueckii, Lactobacillus desidiosus, Lactobacillus divergens, Lactobacillus enterii, Lactobacillus farciminis, Lactobacillus fermentum, Lactobacillus frigidus, Lactobacillus fructivorans, Lactobacillus fructosus, Lactobacillus gasseri, Lactobacillus halotolerans, Lactobacillus helveticus, Lactobacillus heterohiochii, Lactobacillus hilgardii, Lactobacillus hordniae, Lactobacillus inulinus, Lactobacillus jensenii, Lactobacillus jugurti, Lactobacillus kandleri, Lactobacillus kefir, Lactobacillus lactis, Lactobacillus leichmannii, Lactobacillus lindneri, Lactobacillus malefermentans, Lactobacillus mali, Lactobacillus maltaromicus, Lactobacillus minor, Lactobacillus minutus, Lactobacillus mobilis, Lactobacillus murinus, Lactobacillus pentosus, Lactobacillus plantarum, Lactobacillus pseudoplantarum, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus rogosae, Lactobacillus tolerans, Lactobacillus torquens, Lactobacillus ruminis, Lactobacillus sake, Lactobacillus salivarius, Lactobacillus sanfrancisco, Lactobacillus sharpeae, Lactobacillus trichodes, Lactobacillus vaccinostercus, Lactobacillus viridescens, Lactobacillus vitulinus, Lactobacillus xylosus, Lactobacillus yamanashiensis, Lactobacillus zeae, Pediococcus acidlactici, Pediococcus pentosaceus, Streptococcus cremoris, Streptococcus discetylactis, Streptococcus faecium, Streptococcus intermedius, Streptococcus lactis, Streptococcus thermophilus, and combinations thereof. In one embodiment, the lactic acid producing bacterium is Lactobacillus acidophilus. In another embodiment, the Lactobacillus acidophilus strains include the M35, LA45, LA51 and L411 strains. In another embodiment, the Lactobacillus acidophilus strain is LA51. The lactic acid producing bacterium may be administered at a level of at least 1×108 CFU/day. Alternatively, the lactic acid producing bacterium may be administered at a level of about 1×109 CFU/day. The pathogen may be selected from the group consisting of E. coli, Salmonella spp., including Salmonella typhirium, and Staphylococcus aureus. Alternatively, the pathogen may be E. coli O157:H7.
- Another aspect of the invention includes a composition for treating or preventing a pathogenic infection in a ruminant comprising a Lactobacillus acidophilus strain selected from the group consisting of M35, LA45, LA51 and L411 in combination with animal feed. In one embodiment, the Lactobacillus acidophilus strain is LA45 or LA51. In another embodiment, the Lactobacillus acidophilus strain is LA51. The Lactobacillus acidophilus may be present in the animal feed in an amount of greater than 1×108 CFU for each quantity of food equal to the amount eaten by one animal in one day, or the Lactobacillus acidophilus may be present in the animal feed in an amount of about 1×109 CFU for each quantity of food equal to the amount eaten by one animal in one day.
- As already mentioned, strain LA51 is also known as 381-IL-28, and is available under that accession number from the Oklahoma State University collection. While the inventors have characterized LA51 as a Lactobacillus acidophilus, other means of characterization have identified it as Lactobacillus animalis, and Lactobacillus murinus. LA45 is deposited at the American Type Culture Collection under accession number ATCC 53545. M35 and L411 are the accession numbers for those bacteria available from the University of Nebraska.
- Another aspect of the invention includes a method of treating or preventing an intestinal pathogenic infection in a ruminant, the method comprising administering to the ruminant a composition comprising a therapeutically effective amount of a lactic acid producing bacterium and a lactate utilizing bacterium, wherein the lactic acid producing bacterium reduces the quantity of a pathogen in the intestine of the ruminant. The lactic acid producing bacterium may be selected from the group consisting of: Bacillus subtilis, Bifidobacterium adolescentis, Bifidobacterium animalis, Bifidobacterium bifudum, Bifidobacterium infantis, Bifidobacterium longum, Bifidobacterium thermophilum, Lactobacillus acidophilus, Lactobacillus agilis, Lactobacillus alactosus, Lactobacillus alimentarius, Lactobacillus amylophilus, Lactobacillus amylovorans, Lactobacillus amylovorus, Lactobacillus animalis, Lactobacillus batatas, Lactobacillus bavaricus, Lactobacillus bifermentans, Lactobacillus bifidus, Lactobacillus brevis, Lactobacillus buchnerii, Lactobacillus bulgaricus, Lactobacillus catenaforme, Lactobacillus casei, Lactobacillus cellobiosus, Lactobacillus collinoides, Lactobacillus confusus, Lactobacillus coprophilus, Lactobacillus coryniformis, Lactobacillus corynoides, Lactobacillus crispatus, Lactobacillus curvatus, Lactobacillus delbrueckii, Lactobacillus desidiosus, Lactobacillus divergens, Lactobacillus enterii, Lactobacillus farciminis, Lactobacillus fermentum, Lactobacillus frigidus, Lactobacillus fructivorans, Lactobacillus fructosus, Lactobacillus gasseri, Lactobacillus halotolerans, Lactobacillus helveticus, Lactobacillus heterohiochii, Lactobacillus hilgardii, Lactobacillus hordniae, Lactobacillus inulinus, Lactobacillus jensenii, Lactobacillus jugurti, Lactobacillus kandleri, Lactobacillus kefir, Lactobacillus lactis, Lactobacillus leichmannii, Lactobacillus lindneri, Lactobacillus malefermentans, Lactobacillus mali, Lactobacillus maltaromicus, Lactobacillus minor, Lactobacillus minutus, Lactobacillus mobilis, Lactobacillus murinus, Lactobacillus pentosus, Lactobacillus plantarum, Lactobacillus pseudoplantarum, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus rogosae, Lactobacillus tolerans, Lactobacillus torquens, Lactobacillus ruminis, Lactobacillus sake, Lactobacillus salivarius, Lactobacillus sanfrancisco, Lactobacillus sharpeae, Lactobacillus trichodes, Lactobacillus vaccinostercus, Lactobacillus viridescens, Lactobacillus vitulinus, Lactobacillus xylosus, Lactobacillus yamanashiensis, Lactobacillus zeae, Pediococcus acidlactici, Pediococcus pentosaceus, Streptococcus cremoris, Streptococcus discetylactis, Streptococcus faecium, Streptococcus intermedius, Streptococcus lactis, Streptococcus thermophilus, and combinations thereof. The lactate utilizing bacterium may be selected from the group consisting of Megasphaerae eilsdenii, Peptostreptococcus asaccharolyticus, Propionibacterium freudenreichii, Propionibacterium acid-propionici, Propionibacterium freudenreichii, Propionibacterium globosum, Propionibacterium jensenii, Propionibacterium shermanii, Propionibacterium spp., Selenomonas ruminantium, and combinations thereof. In one embodiment, the lactic acid producing bacterium is Lactobacillus acidophilus. In another embodiment, the Lactobacillus acidophilus strain is selected from the group consisting of M35, LA45, LA51 and L411. In another embodiment, the Lactobacillus acidophilus is the LA51 strain. In one embodiment, the lactate utilizing bacterium is Propionibacterium freudenreichii. In another embodiment, the Propionibacterium freudenreichii strain is selected from the group consisting of P9, PF24, P42, P93 and P99. In another embodiment, the Propionibacterium freudenreichii strain is PF24, available from the ATCC under accession number ATCC 9615. The lactate utilizing bacterium and the lactic acid producing bacterium may each be administered in an amount of greater than 1×108 CFU/day, or in an amount of about 1×109 CFU/day. Alternatively, the lactate utilizing bacterium may be administered in an amount of about 1×106 CFU/day. In another embodiment the lactate utilizing bacterium is administered in an amount of greater than 1×106 CFU/day, preferably in an amount of greater than 1×108 CFU/day, and most preferably in an amount of about 1×109 CFU/day.
- Another aspect of the invention includes a composition for treating or preventing a pathogenic infection in a ruminant comprising a Lactobacillus acidophilus strain selected from the group consisting of M35, LA45, LA51, L411, and combinations thereof, in combination with a Propionibacterium freudenreichii strain selected from the group consisting of P9, PF24, P42, P93, P99, and combinations thereof. In one embodiment, the composition further comprises animal feed. In another embodiment, the Lactobacillus acidophilus and the Propionibacterium freudenreichii are each present in the animal feed in an amount of greater than 1×108 CFU for each quantity of food equal to the amount eaten by one animal in one day. In another embodiment, the Lactobacillus acidophilus strain LA51 and Propionibacterium freudenreichii strain PF24 are each present in the animal feed in an amount of about 1×109 CFU for each quantity of food equal to the amount eaten by one animal in one day. In another embodiment, the composition further comprises Lactobacillus acidophilus strain LA45 present in the animal feed in an amount of about 1×106 CFU for each quantity of food equal to the amount eaten by one animal in one day.
- The present invention provides methods and compositions for reducing or eliminating the growth of pathogens in the gut of an animal. In vitroand in vivotests have been conducted utilizing certain strains of microorganisms, which have been found to be particularly effective at inhibiting the growth of many pathogens, including E. coli O157:H7. As used herein, the term “pathogens” refers to any bacterium that produces a harmful effect in a host animal, and especially those bacteria that infect meat and dairy animals and subsequently infect the human food supply, thus causing disease in humans. The invention is considered to be useful in preventing the growth of a wide variety of pathogenic organisms, as demonstrated herein by several tests showing the inhibition of growth of pathogenic bacteria including E. coli, Salmonella spp., including Salmonella typhirium, and Staphylococcus aureus.
- The formulations and methods described herein are applicable to a wide variety of animal species and commercial practices. The inhibition of pathogens in the GIT of animals may be considered for those used in the commercial production of meat, milk, poultry, and fish. In one aspect, the invention includes a method for treating an animal to inhibit the incidence and growth of E. coli O157:H7. The treatment method includes administering a therapeutically effective amount of a selected Lactobacillus acidophilus to an animal that inhibits in vivo growth of E. coli O157:H7. As used herein, the term “therapeutically effective amount” refers to the quantity of bacteria administered to an animal that results in a therapeutic effect by creating an inhospitable environment for pathogens. It has been found that a therapeutically effective amount of Lactobacillus acidophilus can be as little as 1×106 CFU/day when it is administered in combination with other components, although it is preferable that the lactic acid producing bacteria of the invention are administered in an amount of greater than 1×108 CFU/day. It has been found to be particularly effective when the selected Lactobacillus acidophilus is administered at a level of approximately 1×109 CFU/day.
- Among the Lactobacillus acidophilus strains found to be particularly effective as E. coli O157:H7 inhibitors is the 381-IL-28, or the LA51 strain. In one aspect, the invention includes Lactobacillus acidophilus strains that are effective compositions in the above-described methods when provided as a product in the prescribed concentrations for animal consumption as E. coli O157:H7 inhibitors. Before the present invention, Lactobacillus acidophilus microorganisms had been administered as animal feed additives for different purposes such as better utilization of feed-stuffs. For example, U.S. Pat. Nos. 5,534,271 and 5,529,793 (incorporated herein by reference), report that certain combinations of lactic acid producing bacteria and lactate utilizing bacteria could be used in a method to improve the utilization of feedstuffs by ruminants. The present invention, by contrast, sets forth methods for inhibiting pathogenic growth in animals and for improving the quality and quantity of dairy products. However, one aspect of the present invention includes the discovery that certain novel formulations for inhibiting pathogenic growth disclosed herein are also useful for improving the utilization of feedstuffs. To the extent that these formulations were previously unknown for improving utilization of feedstuffs, they form part of the present invention for that purpose.
- In one embodiment, the present invention includes a method for providing a product as an inhibitor of E. coli O157:H7 growth in animals. The method includes selecting a therapeutically effective microorganism as an E. coli O157:H7 inhibitor in animals and producing a product containing this microorganism. Generally, such products require government approval to be certified as pathogen inhibitors; specifically, certification from the United States Department of Agriculture (USDA) is typically required. If the product is for human consumption, for example to counteract an E. coli infection in a human, approval by the United States Food and Drug Administration (FDA) is required.
- An example of a microorganism found to be therapeutically effective is Lactobacillus acidophilus, preferably the LA51 strain, which inhibits in vivo growth of E. coli O157:H7 and other pathogenic microorganisms when administered to animals at a dose of approximately 1×109 CFU/day. Alternatively, a sufficient level may be considered to be at least as much as 1×108 CFU/day. Exact dosage levels can easily be determined by those skilled in the art by evaluating the bile tolerance of the bacteria to be administered in order to verify that viable organisms are delivered to the intestinal tract to compete with and inhibit the growth of pathogenic bacteria such as E. coli O157:H7.
- The present invention identifies several naturally occurring organisms that are capable of inhibiting pathogen growth within the GIT of an animal. Since many pathogens are acid resistant and populate many distinct areas of an animal's digestive tract, the naturally occurring organisms of the invention are preferably capable of inhibiting pathogen growth at a lower pH and in several areas of the GIT; e.g., the rumen, small intestine and large intestine. Earlier research has shown that E. coli O157:H7 populations may be decreased in cattle by feeding hay rations, which in and of itself increases rumen pH to 7.0. However, this has limited application in the finishing or feedlot industries since animals in this phase of the production process are typically fed a diet that has a greater proportion of grain in order to foster better carcass characteristics.
- Microorganisms that are useful in the formulations and methods of the present invention may be capable of producing lactic acid in the GIT. These microorganisms include, for example, the genera Lactobacillus or Enterococcus. Either or both genera may be used. They are distinguished by their ability to utilize sugars such as glucose or lactose or, in the case of Enterococcus, to utilize starch, to produce lactic acid, and thus reduce the local pH level. The choice of microorganism can depend upon the locus at which the desired effect is to be given. For example, the genus Lactobacillus is capable of reducing local pH more than Enterococcus microorganisms.
- Lactic acid producing organisms that may be used in the methods and compositions of the invention include but are not limited to: Bacillus subtilis, Bifidobacterium adolescentis, Bifidobacterium animalis, Bifidobacterlum bifudum, Bifidobacterlum infantis, Bifidobacterlum longum, Bifidobacterium thermophilum, Lactobacillus acidophilus, Lactobacillus agilis, Lactobacillus alactosus, Lactobacillus alimentarius, Lactobacillus amylophilus, Lactobacillus amylovorans, Lactobacillus amylovorus, Lactobacillus animalis, Lactobacillus batatas, Lactobacillus bavaricus, Lactobacillus bifermentans, Lactobacillus bifidus, Lactobacillus brevis, Lactobacillus buchnerii, Lactobacillus bulgaricus, Lactobacillus catenaforme, Lactobacillus casei, Lactobacillus cellobiosus, Lactobacillus collinoides, Lactobacillus confusus, Lactobacillus coprophilus, Lactobacillus coryniformis, Lactobacillus corynoides, Lactobacillus crispatus, Lactobacillus curvatus, Lactobacillus delbrueckii, Lactobacillus desidiosus, Lactobacillus divergens, Lactobacillus enterii, Lactobacillus farciminis, Lactobacillus fermentum, Lactobacillus frigidus, Lactobacillus fructivorans, Lactobacillus fructosus, Lactobacillus gasseri, Lactobacillus halotolerans, Lactobacillus helveticus, Lactobacillus heterohiochii, Lactobacillus hilgardii, Lactobacillus hordniae, Lactobacillus inulinus, Lactobacillus jensenii, Lactobacillus jugurti, Lactobacillus kandleri, Lactobacillus kefir, Lactobacillus lactis, Lactobacillus leichmannii, Lactobacillus lindneri, Lactobacillus malefermentans, Lactobacillus mali, Lactobacillus maltaromicus, Lactobacillus minor, Lactobacillus minutus, Lactobacillus mobilis, Lactobacillus murinus, Lactobacillus pentosus, Lactobacillus plantarum, Lactobacillus pseudoplantarum, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus rogosae, Lactobacillus tolerans, Lactobacillus torquens, Lactobacillus ruminis, Lactobacillus sake, Lactobacillus salivarius, Lactobacillus sanfrancisco, Lactobacillus sharpeae, Lactobacillus trichodes, Lactobacillus vaccinostercus, Lactobacillus viridescens, Lactobacillus vitulinus, Lactobacillus xylosus, Lactobacillus yamanashiensis, Lactobacillus zeae, Pediococcus acidlactici, Pediococcus pentosaceus, Streptococcus cremoris, Streptococcus discetylactis, Streptococcus faecium, Streptococcus intermedius, Streptococcus lactis, Streptococcus thermophllus.
- In one aspect of the invention, any of the above listed lactic acid producing microorganisms may be used to inhibit or treat infections of a host of pathogens, particularly bacterial pathogens including pathogenic bacteria such as Escherichia coli, Staphylococcus aureus, and Salmonella spp., including Salmonella typhirium. These lactic acid producing microorganisms are particularly useful for inhibiting or treating infections of E. coli O157:H7. It has also been found that these organisms may be used for improving the performance of food animals by increasing carcass weight, carcass quality, reducing carcass pathogens, and increasing average daily weight gain and feed efficiency ratio. Any one of these microorganisms may be used for any of these purposes, or any combination of these microorganisms may be used.
- In another aspect, the invention includes a formulation of a combination of lactic acid producing microorganisms, such as those described in the preceding paragraphs, with a second microorganism that enhances the effectiveness of the lactic acid producing microorganisms in competing with pathogenic microorganisms. Enhancing microorganisms that may be used in the formulations of the present invention are preferably lactate utilizing microoorganisms. Examples of lactate utilizing microorganisms useful in the present invention include but are not limited to: Megasphaerae eilsdenii, Peptostreptococcus asaccharolyticus, Propionibacterium freudenreichii, Propionibacterium acid-propionici, Propionibacterium freudenreichii, Propionibacterium globosum, Propionibacterium jensenii, Propionibacterium shermanii, Propionibacterium spp., and Selenomonas ruminantium. A therapeutically effective amount of these enhancing microorganisms is a quantity that produces a beneficial therapeutic effect in the animal to which they are administered, for example, a therapeutically effective amount of these enhancing microorganisms may be greater than 1×106 CFU/day, preferably 1×108 CFU/day, or even more preferably about 1×109 CFU/day.
- The use of specific microorganisms ensures that the desired effect is produced locally. The different microorganisms used in the formulation should be compatible with each other, for example, capable of growing together, and preferably, potentiating the other. Additionally, the microorganisms preferably grow fast at the locus of action. The microorganisms may be selected for various characteristics, such as resistance to bile acids and/or commercial antibiotics, that make them most suited for their intended use.
- In a preferred mode, the formulations of the invention include Lactobacillus acidophilus, Lactobacillus crispatus, or Lactobacillus murinus, either individually or in any combination. In another preferred mode, the formulations of the invention include Lactobacillus acidophilus, Lactobacillus crispatus, or Lactobacillus murinus, either individually or in any combination with each other, and additionally include Propionibacterium freudenreichii or Propionibacterium shermanii or both. Preferably, the formulations of the invention are applied to the daily feed of beef or dairy cattle in a dry supplement, or in a liquid spray applied to the daily feed of the animals. The formulations may be administered once a day or over the course of a day, either in one meal, or divided among the meals, or in any other suitable way.
- Several in vitro tests were conducted that demonstrate the ability of particular bacteria to effectively compete with and interfere with the growth of pathogenic bacteria such as E. coli O157:H7 and others.
- Lyophilized cultures of lactic acid producing and lactate utilizing organisms were selected for their ability to inhibit the growth of pathogens such as E. coli O157:H7, Streptococcus aureus and Salmonella. Combinations of the lactic acid producing and lactate utilizing organisms were further selected for their ability to maximize the inhibition of growth of the various pathogens.
- In order to identify those microorganisms that might be utilized in the method and formulation of the invention, in vitro tests were conducted to identify particularly effective single strains. Seven strains of Propionibacterium and six strains of Lactobacillus were screened for their ability to produce bacteriocins capable of creating zones of inhibition on agar plates that were grown with E. coli O157:H7. The results of those tests are tabulated below.
TABLE 1 Inhibitory Activity of Propionibacterium Strains Grown in Selective Media PATHOGEN P9 P42 P79 P88 P93 P99 PF24 Gram+ B. cereus No No No No No No No S. aureus Yes Yes Yes No No No No Gram− E. coli O157:H7 Yes Yes No No Yes Yes Yes Sal. typhirium No Yes No Yes Yes Yes Yes -
TABLE 2 Inhibitory Activity of Lactobacillus Strains Grown in Selective Media PATHOGEN 30SC 53545 381IL28 C28 FR3 R2 E. coli 43985 −4.1 16.8 91.8 89.7 88.7 64.9 O157:H7 E. coli 933 28.1 −3.4 92.7 93.5 91 89.4 O157:H7 S. aureus 305 −15.6 −22.1 82.6 80.6 84.8 23.3 - From the above tables, it may be appreciated that three strains of Lactobacillus lactic acid producing organisms—381 IL28, C28 and FR3—and four strains of Propionibacterium lactate utilizing organisms—P9, P42, P93 and P99—demonstrate the ability to inhibit the growth of pathogens, in particular, E. coli O157:H7. It should be recognized that combinations of lactic acid producing and lactate utilizing microorganisms can be selected for their ability to maximize the inhibition of growth of various pathogens.
- Selected strains of Lactobacillus acidophilus and Propionibacterium freudenreichii bacteria were grown in an in vitro comparison with E. coli on rich semi-anaerobic media at 38° C. to determine which strains could effectively complete with E. coli growth under in vivo growth conditions. It was found that the LA51 and LA45 strains could substantially out-grow the E coli.
TABLE 3 Growth (Optical Density) of Selected Strains of Bacteria versus E. coli O157:H7 on Rich Semi-Anaerobic Media at 38° C. MINUTES E. coli O157:H7 LA45 LA51 PF24 0 0.2 0.2 0.2 0.2 50 0.3 0.38 0.55 0.3 90 0.45 0.65 0.84 0.35 120 0.60 0.85 1.0 0.36 200 0.80 1.2 1.28 0.38 230 0.85 1.25 1.28 0.39 365 0.90 1.25 1.28 0.50 440 0.90 1.25 1.28 0.58 - In the following in vivo studies, ruminants were inoculated by providing a sufficient quantity of the bacterial strains tested along with necessary growth medium components to the ruminants' intestines by normal ingestion. Inhibited growth of pathogens such as E. coli O157:H7 were observed in feedlot and dairy cattle, as well as other ruminants such as sheep, goats and game. Various inoculation processes were utilized. Examples of these inoculation processes include:
- Placing lyophilized cultures in water, and then spraying or blending the mixture onto the feed of the animal. The mixture can be in dry form, together with additional carriers that are added to the diet of the animal. The diet can include one or more ingredients such as corn, cereal grains, corn byproducts, cereal grain byproducts, alfalfa hay, corn silage, small grain silage, grass hay, plant stalks, oilseed byproducts, protein meals, urea, minerals, molasses, and various fat and oil products.
- Suspending lyophilized cultures in various oils, water and/or compounds for providing a drench to be supplied directly to the animal and the digestive tract of the animal.
- Adding the lyophilized cultures to the drinking water of the animals.
- In vivo tests were conducted with combinations of lactic acid producing and lactate utilizing microorganisms for the inhibition of the pathogen E. coli OP157:H7. The results of those tests are tabulated below in Tables 4 and 5.
TABLE 4 Inhibition of E. coli O157:H7 in Manure at 37° C. TREATMENT 0 Hours 24 Hours Control 5.74 6.56 Combination PF24, LA45, LA51 5.74 4.48 -
TABLE 5 Inhibition of E. coli O157:H7 in Rumen Fluid at 37° C. TREATMENT 0 Hours 24 Hours 48 Hours Control 6.64 6.70 6.79 Combination PF24, LA45, LA51 5.56 5.04 5.00 - The data is reported at log10 CFU E. coli O157:H7/ml. The organisms PF24, LA45 and LA51 are all able to function at a pH of about 4.0 to about 5.0 up to above a pH of about 7.0. In beef production, the chief concern is inhibiting pathogens of cattle on a finishing diet containing high levels of concentrate that tend to decrease rumen pH from about 7.0 to the range of about 5.0 to about 6.9, a range in which the formulation of the present invention preferably functions. While the above in vivo tests illustrate the use of the lactate utilizing organism PF24 and the lactic acid producing organisms LA45 and LA51, it should be understood that the present invention is not limited to these organisms as there are many strains that can be adapted for the formulation and method of the invention.
- In vivo testing has also been conducted with single strains for assessing their effectiveness of pathogen growth inhibition, including E. coli O157:H7. In particular, M35 and LA51 each demonstrate the ability to inhibit shedding of E. coli O157:H7 by about fifty percent above the level of the control animals.
- One hundred and eighty (180) cattle were sorted by weight and put into pens of five (5) animals per pen. During weighing, a fecal sample was taken directly from the rectum of each animal. Initially, only 3 of the 180 animals tested positive for E. coli O157:H7. The animals were monitored for shedding on a bi-weekly basis by taking a composite sample from five fresh droppings on the floor of each pen. Two weeks after the sorting period, twenty-five (25) of the thirty-six (36) pens, or 69%, were positive for E. coli O157:H7. Four weeks after sorting, the prevalence had declined to seven pens that were positive, or 19.4%.
- With approximately sixty days left in the feeding period, the cattle were weighed, resorted, and individual animals were again tested for shedding of the pathogen. A total of twenty-six (26) animals, or 14.4%, were shedding the pathogen. The animals were re-sorted based on weight and shedding pattern. Animal treatment began at this time.
- Two separate treatments utilizing two separate types of lactic acid producing bacteria (NPC 747 and NPC 750) were administered to test their ability to reduce E. coli O157:H7 in the study animals.
- Pen tests taken one week following the beginning of the treatment period indicated that 25% of the pens receiving no treatment were positive for E. coli O157:H7, while 8% of the pens receiving NPC 750 treatment were positive and 0% of the pens receiving NPC 747 treatment were positive. Two weeks after the treatments, 50% of the samples taken from the control (untreated) animals were positive, while only 30% and 20% of the samples from animals receiving NPC 750 and NPC 747 treatments, respectively, were positive for E. coli O157:H7. The tests indicate a reduction in the shedding rate by approximately one-half that of the control for those receiving NPC 747 treatment, which was a greater reduction than for those receiving NPC 750 treatment. All animals shedding E. coli O157:H7 prior to receiving NPC 747 treatment tested negative after receiving the treatment. Furthermore, the pathogen did not spread to other animals in the same pen. The majority of the control animals that tested positive at the beginning of the administration of the treatment continued to test positive, with other animals in the same pen beginning to shed the pathogen.
- On day 42, there were significant (P<0.05) differences among treatments for the individual animal samples. Ten percent (10%) of the animals fed the NPC 747 strain were positive, whereas 20% of the animals fed NPC 750 were positive. In contrast, 58% of the control animals were positive.
- The animals were sampled pre-slaughter. The animals receiving NPC 747 treatment had significantly (P<0.05) less detectable E. coli O157:H7 with only 3.3% of the animals testing positive. The animals receiving the NPC 750 strain and those in the control group were not significantly different, with 15% and 20% shedding, respectively.
- Fecal samples taken in the slaughter plant indicated that 3.3% of the NPC 747 treated animals were positive, 6.6% of the NPC 750 treated animals were positive, and 1 0% of the control animals were positive. Averaging all samples over all sampling times, 61.7% of the control animals shed the pathogen during the feeding period, 51.7% of the NPC 750 animals shed the pathogen, and only 35% of the NPC 747 treated animals shed the pathogen.
- One hundred (100) steers were placed into pens of ten (10) animals per pen. Initially, a fecal sample was taken directly from the rectum of two steers per pen. Another sample was taken 170 days later. The same animals were sampled during both sampling times. A control group receiving no treatment was included in the study. The animals that were treated were treated with the Lactobacillus acidophilus strain LA51 (purchased under the trade name NPC2000). All groups were fed Rumensin and Tylan. The results of the assays are tabulated below.
TABLE 6 Inhibition of E. coli Treated with NPC 2000 Initial Second Final TREATMENT E. coli+ % + E. coli+ % + E. coli+ % + Control 2 of 20 10 4 of 20 20 3 of 20 15 LA51 5 of 20 25 0 of 20 0 0 of 20 0 -
TABLE 7 Animal Performance Data After 198 Days (Final Results) Hot Carcass Average Daily Initial Live Final Live Weight, Weight Gain, TREATMENT Weight, lbs. lbs. lbs. lbs. Control 772 1560 945 3.98 LA 51 772 1626 984 4.31 Response, lb. 66 39 0.33 % Response 4.23 4.12 8.30 - A study was conducted to determine whether food-grade probiotic bacteria could reduce fecal shedding of E. coli O157:H7 in experimentally infected weaned beef calves. The probiotic bacteria in the study included various bovine fecal Lactobacillus spp. isolates that were selected on the basis of high-level in vitro toxic activity against E. coli O157:H7.
- Five 7-month old beef calves were subjected to rumen cannulation surgery and, following recovery, housed in biosafety level 3 isolation rooms. The calves were inoculated intra-ruminally once daily for a sixty-day period with 1×109 CFU of one of the probiotic bacterial strains listed in Table 8 below.
- Two weeks after initiation of probiotic administration, the calves were challenged by intra-ruminal inoculation with E. coli O157:H7 (C1). Fifteen (C2) and twenty seven (C3) days after the first inoculation (C1), the calves were again challenged. The first inoculation C1 comprised a total of about 1×109 CFU of a combination of strains 920, 922, 944 and 966. The second inoculation C2 was with a total of about 1.63×1011 CFU of these strains. The third inoculation C3 included about 1×109 CFU of strain 86-24.
- Prior to and after each challenge, the calves were tested daily for fecal shedding of the inoculum strains. Every two weeks, the animals were tested for evidence of immunity as assessed by serum antibody titers to the Tir protein and O157 lipopolysaccharide (LPS) antigen. The results are shown in Table 8 below. All calves prior to challenge had a relatively high anti-Tir antibody titer that provided the calves with a significant level of immunity against the challenge strains, as all calves, including the control, had a S:C ratio of less than one following the first C1 and second C2 treatments.
TABLE 8 Comparison of the Effect of Feeding Different Lactobacillus spp. Probiotic Strains on E. coli O157:H7 Shedding in Weaned Beef Calves Probiotic strain and time of Antibody Titers No. Days of Shedding:Challenge challenge Tir O157 Shedding Total Shedding Ratio M35 C1 1:12,800 1:12,800 3 1.45 × 106 (S1) 0.00145 (S1/C1) C2 1:12,800 1:12,800 2 3.59 × 106 (S2) 0.000022 (S2/C2) C3 1:12,800 1:12,800 3 3.14 × 108 (S3) 0.314469 (S3/C3) Total 1:51,200 1:51,200 8 3.2 × 108 (S) 0.001936 (S/C) LA45 C1 1:6,400 1:12,800 3 1.8 × 106 (S1) 0.0017955 (S1/C1) C2 1:6,400 1:12,800 2 5.13 × 106 (S2) 0.0000031 (S2/C2) C3 1:6,400 1:12,800 19 1.84 × 1011 (S3) 184.4 (S3/C3) Total 1:12,800 1:51,200 24 1.84 × 1011 (S) 1.1759 (S/C) PBS C1 1:25,600 1:12,800 2 1.0 × 104 (S1) 0.001 (S1/C1) C2 1:25,600 1:12,800 1 1.47 × 109 (S2) 0.009 (S2/C2) C3 1:25,600 1:12,800 8 2.07 × 108 (S3) 0.207 (S3/C3) Total ND 1:51,200 11 1.87 × 109 (S) 0.01 (S/C) LA51 C1 1:6,400 1:12,800 2 9.41 × 106 (S1) 0.0009405 (S1/C1) C2 1:6,400 1:12,800 1 5.13 × 106 (S2) 0.0000031 (S2/C2) C3 ND 1:12,800 9 2.62 × 108 (S3) 0.26163 (S3/C3) Total 1:6,400 1:51,200 12 2.63 × 108 (S) 0.0015944 (S/C) L411 C1 1:12,800 1:6,400 2 1.03 × 104 (S1) 0.001026 (S1/C1) C2 1:12,800 1:6,400 8 6.44 × 108 (S2) 0.0039529 (S2/C2) C3 1:12,800 1:6,400 4 5.13 × 109 (S3) 0.0513 (S3/C3) Total 1:51,200 1:25,600 14 6.97 × 109 (S) 0.0042221 (S/C) - The shedding/challenge ratio in the above table represents the total amount of E. coli O157:H7 shed after inoculation. This number normalizes the values allowing more accurate comparison of the animals and providing more meaningful information than just reviewing the total number of days the cattle shed the organism. M35, LA45, LA51 and L411 represent the various Lactobacillus strains tested. PBS represents the control animal. The total shedding is the CFU per gram in feces times the fecal output in grams on a positive day of shedding times the total number of positive days of shedding.
- Because the anti-Tir titers were not significantly different among the calves, three of the four probiotics have an effect based upon the following reduction in the S:C ratio compared to the control—80% for the calf feed M35, 84% for the calf fed LA51, and 58% for the calf feed 411. Further, the animals fed M35 experienced a 27% reduction in the number of days of shedding compared to the control J3. However, in the animal fed LA51, there was a 9% increase in the number of days of shedding compared to the control J3. Accordingly, feeding probiotics is effective in the reduction of E. coli O157:H7 fecal shedding in cattle.
- A study was conducted to determine whether combinations of lactate utilizing and lactic acid producing bacteria added to the feed of dairy cows could reduce pathogens in and improve the milk production of dairy cows. Three sets of dairy cows were tested. The first set of dairy cows was the control group (Group 1). The second set of dairy cows were administered the lactate utilizing bacterium Propionibacterium freudenreichii strain PF24 in combination with the lactic acid producing bacterium Lactobacillus acidophilus strain NPC 747 in accordance with the methods set forth in the preceding sections (Group 2). The third set of dairy cows were administered the lactate utilizing bacterium Propionibacterium freudenreichii strain PF24 in combination with two stains of the lactic acid producing bacterium Lactobaciullus acidophilus, LA51 (NPC747) and LA45, in accordance with the methods set forth in the preceding sections (Group 3). The results of this study are set forth in table 9.
- Table 9 demonstrates the effects of each of the treatment regimes on the milk production, body weight, and feed consumption of the dairy cows. The data demonstrates that treatments involving feeding the dairy cows lactate utilizing bacteria in combination with lactic acid producing bacteria resulted in statistically significant improvements in the quantity of milk produced, the quantity of fat corrected milk produced (i.e., milk with a higher fat content is weighted more), the ratio of fat corrected milk produced per quantity of feed consumed, the quantity of energy corrected milk produced (i.e., milk with a higher calorie content is weighted more), the quantity of energy corrected milk produced per quantity of feed consumed, the quantity of milk fat in the milk produced, and the urea content of the cows' blood serum. The addition of the LA45 strain in Group 3 resulted in an increase in the urea content of the cows' blood serum.
TABLE 9 The Effect of Addition of Bacterial Cultures on Performance Variables for Lactating Dairy Cows Treatment Contrasts (P < 0.10) Treatments Standard Group 1 vs. Group 2 Variable Group 1 Group 2 Group 3 Error Groups 2 and 3 vs. Group 3 DMI2, kg/day 25.5 26.2 26.3 0.5 NS1 NS Milk, kg/day 37.7 39.6 38.5 0.7 0.08 NS FCM3, kg/day 34.9 37.8 37.6 0.8 0.007 NS Milk/DMI, kg/kg 1.45 1.53 1.48 0.04 NS NS FCM/DMI, kg/kg 1.35 1.45 1.44 0.03 0.03 NS ECM4, kg/day 34.5 36.8 37.0 0.8 0.03 NS ECM/DMI, kg/kg 1.34 1.42 1.41 0.04 0.03 NS Milk fat, % 3.19 3.23 3.40 0.10 NS NS Milk fat, kg/day 1.15 1.27 1.29 0.04 0.02 NS Milk protein, % 2.95 2.94 3.00 0.05 NS NS Milk protein, kg/day 1.09 1.13 1.12 0.03 NS NS Somatic cells/ml, 259 198 257 111 NS NS ×1000 Final Body Weight, 667.6 658.3 664.1 6.5 NS NS kg Body Weight Change, 28.9 20.8 21.2 7.3 NS NS kg Serum urea N, mg/dl 22.62 20.43 21.66 0.48 0.01 0.08 Serum glucose, mg/dl 64.73 67.55 65.52 1.19 NS NS
1Not statistically significant for P > 0.10
2Dry matter intake
33.5% fat-corrected milk
4Energy-corrected milk for comparison on an equivalent calorie basis
- Table 10 shows a marked reduction in the occurrence of the pathogen E. coli O157:H7 in fecal samples from each of the sets of dairy cows to which the combination of lactate utilizing bacteria and lactic acid producing bacteria were administered. The effect was particularly pronounced in the dairy cows administered both the LA51 (NPC747) and LA45 strains of L. acidophilus in combination with the PF24 strain of P. freudenreichii. In this set of cows, no E. coli O157:H7 was detected in any fecal samples.
TABLE 10 Occurrence of E. coli O157:H7 in Fecal Samples from Dairy Cows Group 1 Group 2 Group 3 E. coli O157:H7 19% 12% 0% occurrence - A study was conducted to determine whether particular novel combinations of bacteria could reduce the occurrence of pathogenic bacteria. It was also found that these combinations improved the feeding efficiency of cattle. Two hundred forty (240) steers were assigned to 48 pens of five head each. The average weight of the steers was 780 lbs. Each pen was allotted one of four treatments: (1) group 1 was the control group and was fed no microorganisms, (2) group 2 was fed two strains: Propionibacterium freudenreichii strain PF24 and Lactobacillus acidophilus strain LA51 (NPC747), each strain in an amount of 1×109 CFU/day, (3) group 3 was fed three strains: PF24 in an amount of 1×109 CFU/day, LA51 (NPC747) in an amount of 1×109 CFU/day, and Lactobacillus acidophilus strain LA45 in an amount of 1×106 CFU/day, and (4) group 4 was fed three strains: PF24 in an amount of 1×109 CFU/day, LA51 (NPC747) in an amount of 1×106 CFU/day, and Lactobacillus acidophilus strain LA45 in an amount of 1×106 CFU/day.
- Table 11 demonstrates an improvement in the feeding efficiencies of the groups administered the novel combinations of bacteria. All of the groups administered the novel combinations of bacteria exhibited a greater average daily weight gain over the course of 56 and 1 40 days relative to the control group.
TABLE 11 Feed Efficiencies Average Over Days 0-56 Average Over Days 0-140 Average Daily Average Daily Gain Feed Intake Gain Feed Intake Group 1 4.42 lbs. 19.16 lbs. 3.62 lbs. 18.82 lbs. (control) Group 2 4.52 lbs. 19.62 lbs. 3.70 lbs. 19.32 lbs. Group 3 4.54 lbs. 19.24 lbs. 3.72 lbs. 18.79 lbs. Group 4 4.61 lbs. 19.61 lbs. 3.69 lbs. 19.31 lbs. - Table 12 demonstrates a substantial improvement in the quantity of E. coli O157:H7 found in the carcasses and hides of the steers following slaughter. Notably, the carcasses of the steers in Group 2 exhibited less than half of this pathogen than the control group, and the carcasses of the steers in the other two groups also exhibited a substantial reduction in the quantity of this pathogen. Particularly notable is the dramatic reduction in the quantity of E. coli in the hides of all of the steers who were administered the formulations of the invention.
TABLE 12 E. coli O157:H7 incidence Carcass Hide Group 1 (control) 33.3% 20% Group 2 13.3% 0% Group 3 26.6% 0% Group 4 20% 0% - A study was conducted to determine which of several methods of controlling pathogenic growth in cattle was superior. The first method involved feeding the bacteria NPC 747 and NPC 750 (also known as M35, available under that name from the University of Nebraska) to cattle. The second method involved removing starch from the cattle's diet. The third method involved pen cleaning. The study design was 3 H 2 H 2 factorial. A finishing diet (33% high moisture corn, 20% dry rolled corn, 40% wet corn gluten feed, and 7% alfalfa, with vitamins, minerals, Rumensin, and Tylan) was fed to 432 steers (average weight 340 kg) in 54 pens, with 8 steers in each pen. The bacteria NPC 747 and NPC 750 was fed daily to the cattle in 1 8 pens. Half the pens were cleaned monthly, and the other half were cleaned only at the end of the study. Two weeks prior to slaughter, the diet was changed for half the cattle, with corn bran replacing corn in the cattle's feed.
- Neither the first nor third methods affected steer performance (P>0.39), but diet change reduced DMI (P<0.001; 12.8 kg/d versus 11.5 kg/d) during the last two weeks, and reduced ADG and efficiency for the entire feeding period (P<0.001). Carcass weight was reduced 8.4 kg by diet change.
- Individual fecal samples were obtained monthly and 0, 1, and 2 weeks prior to slaughter and analyzed for E. coli O157:H7. An entire pen was the experimental detection unit, and a pen was deemed positive for E. coli O157:H7 if any of the 8 steers was positive. Overall detection of E. coli O157:H7 was low (145/3024 animal-weeks). The second and third methods had no effect on E. coli O157:H7 prevalence. The first method numerically reduced E. coli O157 positive pens the week of marketing (44% versus 17%; P=0.10).
- While various embodiments of the invention have been described above, it should be understood that they have been presented by way of example only, and not limitation. Thus, the breadth and scope of the present invention should not be limited by any of the above-described exemplary embodiments, but should be defined only in accordance with the following claims and their equivalents.
Claims (67)
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/160,470 US20060110367A1 (en) | 2002-01-08 | 2005-06-24 | Compositions and methods for inhibiting pathogenic growth |
US11/843,540 US8071088B2 (en) | 2002-01-08 | 2007-08-22 | Compositions and methods for reducing the pathogen content of meat and meat products |
US12/421,449 US8697053B2 (en) | 2002-01-08 | 2009-04-09 | Compositions and methods for inhibiting pathogenic growth |
US13/082,234 US8496925B2 (en) | 2002-01-08 | 2011-04-07 | Compositions and methods for reducing the pathogen content of meat or meat products |
US13/951,140 US8980611B2 (en) | 2002-10-01 | 2013-07-25 | Compositions and methods for reducing the pathogen content of meat or meat products |
US15/288,870 US20170020935A1 (en) | 2002-01-08 | 2016-10-07 | Compositions and methods for inhibiting pathogenic growth |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31905402P | 2002-01-08 | 2002-01-08 | |
US31958702P | 2002-10-01 | 2002-10-01 | |
US10/273,141 US20040028665A1 (en) | 2002-01-08 | 2002-10-18 | Compositions and methods for inhibiting pathogenic growth |
US10/288,487 US7063836B2 (en) | 2002-01-08 | 2002-11-06 | Compositions and methods for inhibiting pathogenic growth |
US11/160,470 US20060110367A1 (en) | 2002-01-08 | 2005-06-24 | Compositions and methods for inhibiting pathogenic growth |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/288,487 Continuation US7063836B2 (en) | 2002-01-08 | 2002-11-06 | Compositions and methods for inhibiting pathogenic growth |
US10/905,215 Division US20050244390A1 (en) | 2002-01-08 | 2004-12-21 | Compositions and methods for inhibiting pathogenic growth |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/707,674 Continuation US7291326B2 (en) | 2002-01-08 | 2003-12-31 | Compositions and methods for reducing the pathogen content of meat and meat products |
US11/843,540 Continuation US8071088B2 (en) | 2002-01-08 | 2007-08-22 | Compositions and methods for reducing the pathogen content of meat and meat products |
US12/421,449 Continuation US8697053B2 (en) | 2002-01-08 | 2009-04-09 | Compositions and methods for inhibiting pathogenic growth |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060110367A1 true US20060110367A1 (en) | 2006-05-25 |
Family
ID=46204616
Family Applications (10)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/273,141 Abandoned US20040028665A1 (en) | 2002-01-08 | 2002-10-18 | Compositions and methods for inhibiting pathogenic growth |
US10/288,487 Expired - Lifetime US7063836B2 (en) | 2002-01-08 | 2002-11-06 | Compositions and methods for inhibiting pathogenic growth |
US10/288,490 Abandoned US20030175307A1 (en) | 2002-01-08 | 2002-11-06 | Compositions and methods for inhibiting pathogenic growth |
US10/905,217 Expired - Lifetime US7291328B2 (en) | 2002-01-08 | 2004-12-21 | Method to enhance fat content in the milk of a diary cow |
US10/905,215 Abandoned US20050244390A1 (en) | 2002-01-08 | 2004-12-21 | Compositions and methods for inhibiting pathogenic growth |
US10/905,216 Expired - Fee Related US7291327B2 (en) | 2002-01-08 | 2004-12-21 | Compositions and methods for inhibiting pathogenic growth |
US11/160,470 Abandoned US20060110367A1 (en) | 2002-01-08 | 2005-06-24 | Compositions and methods for inhibiting pathogenic growth |
US11/932,278 Active 2024-12-02 US8734785B2 (en) | 2002-01-08 | 2007-10-31 | Compositions to inhibit pathogenic growth |
US12/421,449 Expired - Lifetime US8697053B2 (en) | 2002-01-08 | 2009-04-09 | Compositions and methods for inhibiting pathogenic growth |
US14/285,306 Abandoned US20140255350A1 (en) | 2002-01-08 | 2014-05-22 | Composition And Methods For Inhibiting Pathogenic Growth |
Family Applications Before (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/273,141 Abandoned US20040028665A1 (en) | 2002-01-08 | 2002-10-18 | Compositions and methods for inhibiting pathogenic growth |
US10/288,487 Expired - Lifetime US7063836B2 (en) | 2002-01-08 | 2002-11-06 | Compositions and methods for inhibiting pathogenic growth |
US10/288,490 Abandoned US20030175307A1 (en) | 2002-01-08 | 2002-11-06 | Compositions and methods for inhibiting pathogenic growth |
US10/905,217 Expired - Lifetime US7291328B2 (en) | 2002-01-08 | 2004-12-21 | Method to enhance fat content in the milk of a diary cow |
US10/905,215 Abandoned US20050244390A1 (en) | 2002-01-08 | 2004-12-21 | Compositions and methods for inhibiting pathogenic growth |
US10/905,216 Expired - Fee Related US7291327B2 (en) | 2002-01-08 | 2004-12-21 | Compositions and methods for inhibiting pathogenic growth |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/932,278 Active 2024-12-02 US8734785B2 (en) | 2002-01-08 | 2007-10-31 | Compositions to inhibit pathogenic growth |
US12/421,449 Expired - Lifetime US8697053B2 (en) | 2002-01-08 | 2009-04-09 | Compositions and methods for inhibiting pathogenic growth |
US14/285,306 Abandoned US20140255350A1 (en) | 2002-01-08 | 2014-05-22 | Composition And Methods For Inhibiting Pathogenic Growth |
Country Status (1)
Country | Link |
---|---|
US (10) | US20040028665A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080026098A1 (en) * | 2002-01-08 | 2008-01-31 | Nutrition Physiology Corporation | Compositions and methods for reducing the pathogen content of meat and meat products |
US20090203031A1 (en) * | 2003-08-29 | 2009-08-13 | Garner Bryan E | Methods for Detecting and Quantifying Specific Microorganisms |
US20090203030A1 (en) * | 2003-08-29 | 2009-08-13 | Garner Bryan E | Methods for Detecting and Quantifying Specific Probiotic Microorganisms in Animal Feed |
US8697053B2 (en) | 2002-01-08 | 2014-04-15 | Nutrition Physiology Company, Llc | Compositions and methods for inhibiting pathogenic growth |
US20200040412A1 (en) * | 2016-10-03 | 2020-02-06 | Bio-Cat, Inc. | Bacillus compositions and uses thereof |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140286919A1 (en) * | 2002-01-08 | 2014-09-25 | Nutrition Physilogy Company, LLC | Composition And Methods For Inhibiting Pathogenic Growth |
US20050130288A1 (en) * | 2003-12-11 | 2005-06-16 | Eromlife Co., Ltd. | Novel microorganism Pediococcus pentosaceus EROM101, having immune enhancement, anticancer and antimicrobial activities |
ES2336222T3 (en) * | 2004-05-28 | 2010-04-09 | Suntory Holdings Limited | A COMPOSITION THAT HAS IMMUNOR REGULATORY ACTIVITIES THAT LACTOBACILLUS PENSOSUS INCLUDES. |
JP4515157B2 (en) * | 2004-05-28 | 2010-07-28 | サントリーホールディングス株式会社 | Lactic acid bacteria with immunomodulatory action |
US20100080783A1 (en) * | 2004-11-22 | 2010-04-01 | Watson James B | Microbial feed additive |
US20080095890A1 (en) * | 2004-11-22 | 2008-04-24 | Watson James B | Microbial feed additive |
JP5322653B2 (en) | 2005-11-28 | 2013-10-23 | ザイモジェネティクス, インコーポレイテッド | IL-21 antagonist |
US7613330B2 (en) * | 2006-04-03 | 2009-11-03 | Jbs Swift & Company | Methods and systems for tracking and managing livestock through the production process |
US7606394B2 (en) | 2006-04-03 | 2009-10-20 | Jbs Swift & Company | Methods and systems for administering a drug program related to livestock |
US9159126B2 (en) | 2006-04-03 | 2015-10-13 | Jbs Usa, Llc | System and method for analyzing and processing food product |
PL210465B1 (en) * | 2007-06-04 | 2012-01-31 | Inst Biotechnologii Surowic I Szczepionek Biomed Społka Akcyjna | Composition of strains type Lactobacillus and application of the composition of strains type Lactobacillus |
RU2504552C2 (en) | 2007-12-07 | 2014-01-20 | Займодженетикс, Инк. | Monoclonal antibodies against il-21 of human being |
CN102272332A (en) * | 2009-01-12 | 2011-12-07 | 丹尼斯科公司 | Lactic acid bacteria and their use in swine direct-fed microbials |
NZ600700A (en) * | 2009-12-25 | 2014-05-30 | Meiji Feed Co Ltd | Composition containing bacterium capable of producing propionic acid bacterium, and use thereof |
US9492487B2 (en) * | 2010-02-01 | 2016-11-15 | Matthew Ryan Garner | Microbial product containing multiple microorganisms |
US8445226B2 (en) | 2010-02-01 | 2013-05-21 | Microbios, Inc. | Process and composition for the manufacture of a microbial-based product |
US7888062B1 (en) | 2010-02-01 | 2011-02-15 | Microbios, Inc. | Process and composition for the manufacture of a microbial-based product |
DE102010013209A1 (en) * | 2010-03-29 | 2011-09-29 | Technische Universität München | Diarrhea prophylactic |
US9011838B2 (en) * | 2010-04-20 | 2015-04-21 | Nutrition Physiology Company, Llc | Low/high dose probiotic supplements and methods of their use |
CN101822322B (en) * | 2010-06-22 | 2012-08-15 | 金银卡(广州)生物科技有限公司 | preparation method of agent of lactic acid bacteria for relieving dysentery |
WO2012044984A1 (en) | 2010-09-30 | 2012-04-05 | The Board Of Trustees Of The University Of Arkansas | Methods of selecting and using therapeutic and prophylactic probiotic cultures to reduce bacterial pathogen loads |
CN102106463B (en) * | 2011-01-31 | 2012-12-05 | 杨永浩 | Microbial feed additives and preparation method thereof |
US20130017174A1 (en) * | 2011-07-12 | 2013-01-17 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods for increasing health and reducing pathogenic bacteria in animals |
MX2014005754A (en) * | 2011-11-11 | 2015-02-10 | Nutrition Physiology Company Llc | Lactic acid bacteria and their use as dietary supplementals for poultry. |
CN102409015B (en) * | 2011-12-06 | 2014-04-16 | 北京大北农科技集团股份有限公司 | Composite micro-ecological preparation as well as premixed material and application of preparation in feed additive |
WO2013130624A2 (en) * | 2012-02-28 | 2013-09-06 | Cornell University | Probiotic compositions and methods |
US11951138B2 (en) | 2013-03-14 | 2024-04-09 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) | Microbial compositions comprising rumen microflora and uses thereof |
EP2826385A1 (en) * | 2013-07-18 | 2015-01-21 | Danstar Ferment AG | Stability of silage inoculants and methods for improving aerobic stability of silage |
US10420806B2 (en) | 2013-12-30 | 2019-09-24 | Texas Tech University System | Lactic acid and other probiotic bacteria to reduce pathogens in lymph nodes and other lymphatic tissues of livestock animals |
CN105543126A (en) * | 2015-12-25 | 2016-05-04 | 西北农林科技大学 | Lactobacillus plantarum JM113 and application thereof |
MX2018013050A (en) | 2016-04-26 | 2019-03-06 | The State Of Israel Ministry Of Agriculture & Rural Development Agricultural Res Organization Aro Vo | Regulation of feed efficiency and methane production in ruminating animals. |
US9694042B1 (en) | 2016-05-23 | 2017-07-04 | Kaeco Group, Inc. | Mastic gum top dressing for the prevention of gastrointestinal distress in horses and other species |
US11439676B2 (en) | 2018-10-16 | 2022-09-13 | Kaeco Group, Inc. | Method for prevention or treating gastrointestinal distress in humans using mastic gum compositions |
US10548917B2 (en) * | 2016-05-23 | 2020-02-04 | Kaeco Group Inc. | Supplement for the prevention and treatment of gastrointestinal distress in horses and other species |
CN106259459B (en) * | 2016-07-22 | 2018-08-07 | 青岛科拓恒通乳酸菌产业化开发研究院有限公司 | A kind of lactic acid bacteria compound formulation and its application improving potato starch and dry matter content |
CN106305785B (en) * | 2016-07-22 | 2018-10-02 | 青岛科拓恒通乳酸菌产业化开发研究院有限公司 | It is a kind of to improve the composite bacteria agent of content beta-carotene and its application in carrot |
CN106259460B (en) * | 2016-07-22 | 2018-10-02 | 青岛科拓恒通乳酸菌产业化开发研究院有限公司 | A kind of composite bacteria agent and its application improving total reducing sugar and yield in carrot |
CN107889935A (en) * | 2017-12-04 | 2018-04-10 | 大连百安泰生物科技有限公司 | A kind of semi-moist shape probiotic composition and preparation method and application |
CN110016442B (en) * | 2019-02-21 | 2021-03-23 | 河北一然生物科技有限公司 | Application of lactobacillus rhamnosus and compound bacterium powder thereof in product for preventing and treating vaginitis |
CN110577912B (en) * | 2019-09-24 | 2022-03-29 | 华南理工大学 | Lactobacillus gasseri and application thereof in preparing fermented milk |
WO2021146582A1 (en) | 2020-01-17 | 2021-07-22 | AgBiome, Inc. | Compositions and methods for controlling undesirable microbes and improving animal health |
CN112760247B (en) * | 2020-11-10 | 2022-10-25 | 深圳华大生命科学研究院 | Lactobacillus rhamnosus for preventing and/or treating diseases caused by genital tract flora disorder and/or bone loss |
WO2023044111A1 (en) * | 2021-09-17 | 2023-03-23 | Biomedit, Llc | Probiotic compositions for aquaculture |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946791A (en) * | 1986-10-02 | 1990-08-07 | Bio Techniques Laboratories, Inc. | Novel strain of Lactobacillus acidophilus |
US5179020A (en) * | 1991-08-19 | 1993-01-12 | Bio Techniques Laboratories, Inc. | Antibiotic resistant strain of lactobacillus acidophilus |
US5529793A (en) * | 1994-11-16 | 1996-06-25 | Nutrition Physiology Corporation | Compositions for improving the utilization of feedstuffs by ruminants |
US5534271A (en) * | 1994-11-16 | 1996-07-09 | Nutrition Physiology | Process for improving the utilization of feedstuffs by ruminants |
US7063836B2 (en) * | 2002-01-08 | 2006-06-20 | Garner Bryan E | Compositions and methods for inhibiting pathogenic growth |
US7291326B2 (en) * | 2003-01-06 | 2007-11-06 | Nutrition Physiology Corporation | Compositions and methods for reducing the pathogen content of meat and meat products |
US7323166B2 (en) * | 2002-06-19 | 2008-01-29 | Board Of Regents University Of Nebraska | Lactic acid bacteria cultures that inhibit food-borne pathogens |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE371209B (en) | 1969-10-13 | 1974-11-11 | Cernelle Ab | |
US3875306A (en) | 1969-11-24 | 1975-04-01 | Wenner Gren Medical Lab Aktieb | Animal feed supplement |
US3821416A (en) | 1971-07-01 | 1974-06-28 | Univ Missouri | Dried brewers grain in high energy animal feeds |
US3857971A (en) | 1973-02-09 | 1974-12-31 | Grace W R & Co | Ruminant feed additive and method of preparing the same |
US3956482A (en) | 1973-06-25 | 1976-05-11 | W. R. Grace & Co. | Milk production |
US3984575A (en) | 1974-02-06 | 1976-10-05 | Microlife Technics, Inc. | Bacterial compositions for changing the digestive system bacteria in animals |
US4172127A (en) | 1975-09-04 | 1979-10-23 | Research Corporation | Treatment of ruminants |
US4112069A (en) | 1975-09-04 | 1978-09-05 | Research Corporation | Treatment of ruminants |
US4138498A (en) | 1976-12-07 | 1979-02-06 | W. R. Grace & Co. | Ruminant feed additive |
US4518696A (en) | 1983-01-11 | 1985-05-21 | Chr. Hansen's Laboratory, Inc. | Stabilized liquid bacterial suspension for oral administration to animals |
GB8314025D0 (en) | 1983-05-20 | 1983-06-29 | Pharmaindev Ltd | Electrostatic coating of materials |
US4956295A (en) | 1984-05-21 | 1990-09-11 | Chr. Hansen's Laboratory, Inc. | Stabilization of dried bacteria extended in particulate carriers |
US5139777A (en) | 1984-08-15 | 1992-08-18 | Richter Cedeon Vegveszeti | Composition and method for improving the efficiency of ruminant feed utilization |
US4814273A (en) * | 1985-03-20 | 1989-03-21 | Michigan Biotechnology Institute | Production of organic acids by an improved fermentation process |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
GB8606805D0 (en) | 1986-03-19 | 1986-04-23 | Allied Colloids Ltd | Water-absorbing polymers |
SE454230C (en) | 1986-04-07 | 1990-03-05 | Medipharm Ab | PROCEDURE FOR SUPPLY OF LOW CONTENTS BIOLOGICALLY ACTIVE MATERIAL TO BASIC MATERIAL, SUCH AS PROCESSED FOOD OR ANIMAL FEED |
US4777051A (en) | 1986-06-20 | 1988-10-11 | Ajinomoto Co., Inc. | Process for the production of a composition for animal feed |
US4980164A (en) | 1986-10-02 | 1990-12-25 | Bio Techniques Laboratories, Inc. | Strains of lactobacillus for enhancing feed conversion efficiency |
US4868110A (en) | 1986-10-06 | 1989-09-19 | Biocontrol Systems, Inc. | Methods and device for detection of microorganisms |
SE8702435L (en) | 1987-06-11 | 1988-12-12 | Medipharm Ab | COULD INCREASE THE PROTEIN CONTENTS IN MILK WITH MILK PRODUCING ANIMALS |
US4910024A (en) | 1988-07-05 | 1990-03-20 | Micro Chemical, Inc. | Method and apparatus for administering live bacteria as feed additives to livestock and poultry |
US5069922A (en) | 1989-02-09 | 1991-12-03 | Eugene Brotsky | Process for treating poultry carcasses to control salmonellae growth |
NL8901731A (en) | 1989-07-06 | 1991-02-01 | Stork Pmt | METHOD FOR KILLING BACTERIA IN GENDER POULTRY |
JPH06102610B2 (en) * | 1990-03-23 | 1994-12-14 | 花王株式会社 | Hair cosmetics |
JPH04228097A (en) | 1990-07-02 | 1992-08-18 | Toyo Ink Mfg Co Ltd | Method for separating and concentrating cell from milk sample and kit therefor |
US5139792A (en) | 1990-07-19 | 1992-08-18 | Bio-Techniques Laboratories, Inc. | Method and system for dispensing live bacteria into animal feed and drinking water |
US5256425A (en) | 1991-08-19 | 1993-10-26 | Bio Techniques Laboratories, Inc. | Antibiotic resistant strain of lactobacillus acidophilus |
US6287610B1 (en) | 1991-11-20 | 2001-09-11 | Monfort, Inc. | Method for increasing the tenderness of a meat product |
US5374433A (en) | 1991-11-20 | 1994-12-20 | Monfort, Inc. | Method for preserving food products |
US5869113A (en) | 1991-11-20 | 1999-02-09 | Monfort, Inc. | Method for preserving food products and food products made thereby |
ATE207966T1 (en) | 1993-09-13 | 2001-11-15 | Canon Kk | DETERMINATION OF NUCLEIC ACIDS BY PCR, MEASURING THE NUMBER OF MICROBIAL CELLS, GENES OR GENE COPIES BY PCR AND KIT FOR THEIR USE |
US5702944A (en) | 1994-07-25 | 1997-12-30 | Micro Test, Inc. | Microbial transport media |
FR2758051B1 (en) | 1997-01-06 | 1999-12-17 | Cobiotex | METHODS FOR SYSTEMATICALLY ERADICATING THE CARRYING OF PATHOGENS BY ANIMALS AND COMPOSITIONS USED THEREIN |
US5900266A (en) | 1997-05-29 | 1999-05-04 | The Curators Of The University Of Missouri | Heat-treated lactic and/or glycolic acid compositions and methods of use |
EP2365083A1 (en) | 1997-05-30 | 2011-09-14 | Chr. Hansen A/S | Lactic acid bacterial starter cultures and compositions thereof |
US6455063B1 (en) | 1998-04-17 | 2002-09-24 | The Board Of Regents For Oklahoma State University | Propionibacterium P-63 for use in direct fed microbials for animal feeds |
WO2001090311A1 (en) | 2000-05-25 | 2001-11-29 | Societe Des Produits Nestle S.A. | Novel probiotics for pet food applications |
AU2001284558B2 (en) * | 2000-08-08 | 2007-01-04 | Genesis Research And Development Corporation Limited | Lactobacillus rhamnosus polynucleotides, polypeptides and methods for using them |
AU2002246679B2 (en) | 2000-12-18 | 2006-11-16 | Probiohealth Llc | Probiotic compounds derived from lactobacillus casei strain KE01 |
US20030175305A1 (en) | 2002-01-08 | 2003-09-18 | Garner Bryan E. | Compositions and methods for inhibiting pathogenic growth |
ITMI20020399A1 (en) | 2002-02-28 | 2003-08-28 | Ct Sperimentale Del Latte S P | DIETARY AND / OR PHARMACEUTICAL COMPOSITIONS FOR HUMAN AND / OR ANIMAL USE BASED ON MICROBIAL PROBIOTIC PREPARATIONS |
JP4521687B2 (en) | 2002-06-21 | 2010-08-11 | ニューキャッスル イノベーション リミテッド | Probiotics, Propionibacterium ienseni 702 |
CA2820023A1 (en) | 2002-09-26 | 2007-12-19 | Vita-Herb Nutriceuticals, Inc. | Prebiotic and preservative uses of oil-emulsified probiotic encapsulations |
US20050153033A1 (en) | 2003-06-27 | 2005-07-14 | Stiles Michael E. | Lactic acid bacteria for the treatment of food |
-
2002
- 2002-10-18 US US10/273,141 patent/US20040028665A1/en not_active Abandoned
- 2002-11-06 US US10/288,487 patent/US7063836B2/en not_active Expired - Lifetime
- 2002-11-06 US US10/288,490 patent/US20030175307A1/en not_active Abandoned
-
2004
- 2004-12-21 US US10/905,217 patent/US7291328B2/en not_active Expired - Lifetime
- 2004-12-21 US US10/905,215 patent/US20050244390A1/en not_active Abandoned
- 2004-12-21 US US10/905,216 patent/US7291327B2/en not_active Expired - Fee Related
-
2005
- 2005-06-24 US US11/160,470 patent/US20060110367A1/en not_active Abandoned
-
2007
- 2007-10-31 US US11/932,278 patent/US8734785B2/en active Active
-
2009
- 2009-04-09 US US12/421,449 patent/US8697053B2/en not_active Expired - Lifetime
-
2014
- 2014-05-22 US US14/285,306 patent/US20140255350A1/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946791A (en) * | 1986-10-02 | 1990-08-07 | Bio Techniques Laboratories, Inc. | Novel strain of Lactobacillus acidophilus |
US5179020A (en) * | 1991-08-19 | 1993-01-12 | Bio Techniques Laboratories, Inc. | Antibiotic resistant strain of lactobacillus acidophilus |
US5529793A (en) * | 1994-11-16 | 1996-06-25 | Nutrition Physiology Corporation | Compositions for improving the utilization of feedstuffs by ruminants |
US5534271A (en) * | 1994-11-16 | 1996-07-09 | Nutrition Physiology | Process for improving the utilization of feedstuffs by ruminants |
US7063836B2 (en) * | 2002-01-08 | 2006-06-20 | Garner Bryan E | Compositions and methods for inhibiting pathogenic growth |
US7323166B2 (en) * | 2002-06-19 | 2008-01-29 | Board Of Regents University Of Nebraska | Lactic acid bacteria cultures that inhibit food-borne pathogens |
US7291326B2 (en) * | 2003-01-06 | 2007-11-06 | Nutrition Physiology Corporation | Compositions and methods for reducing the pathogen content of meat and meat products |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080026098A1 (en) * | 2002-01-08 | 2008-01-31 | Nutrition Physiology Corporation | Compositions and methods for reducing the pathogen content of meat and meat products |
US8071088B2 (en) | 2002-01-08 | 2011-12-06 | Guardian Food Technologies, Llc | Compositions and methods for reducing the pathogen content of meat and meat products |
US8697053B2 (en) | 2002-01-08 | 2014-04-15 | Nutrition Physiology Company, Llc | Compositions and methods for inhibiting pathogenic growth |
US8734785B2 (en) | 2002-01-08 | 2014-05-27 | Nutrition Physiology Company, Llc | Compositions to inhibit pathogenic growth |
US20090203031A1 (en) * | 2003-08-29 | 2009-08-13 | Garner Bryan E | Methods for Detecting and Quantifying Specific Microorganisms |
US20090203030A1 (en) * | 2003-08-29 | 2009-08-13 | Garner Bryan E | Methods for Detecting and Quantifying Specific Probiotic Microorganisms in Animal Feed |
US20200040412A1 (en) * | 2016-10-03 | 2020-02-06 | Bio-Cat, Inc. | Bacillus compositions and uses thereof |
US10787716B2 (en) * | 2016-10-03 | 2020-09-29 | Bio-Cat, Inc. | Bacillus compositions and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
US20030175306A1 (en) | 2003-09-18 |
US20050238630A1 (en) | 2005-10-27 |
US7063836B2 (en) | 2006-06-20 |
US20030175307A1 (en) | 2003-09-18 |
US20140255350A1 (en) | 2014-09-11 |
US20080057045A1 (en) | 2008-03-06 |
US8734785B2 (en) | 2014-05-27 |
US20040028665A1 (en) | 2004-02-12 |
US20120107288A1 (en) | 2012-05-03 |
US20050244391A1 (en) | 2005-11-03 |
US8697053B2 (en) | 2014-04-15 |
US7291327B2 (en) | 2007-11-06 |
US20050244390A1 (en) | 2005-11-03 |
US7291328B2 (en) | 2007-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7291328B2 (en) | Method to enhance fat content in the milk of a diary cow | |
AU2010203120B2 (en) | Compositions and methods for inhibiting pathogenic growth | |
US8980611B2 (en) | Compositions and methods for reducing the pathogen content of meat or meat products | |
US20230071245A1 (en) | Compositions and methods for controlling undesirable microbes and improving animal health | |
US20150224154A1 (en) | Low/High Dose Probiotic Supplements And Methods Of Their Use | |
US20170020935A1 (en) | Compositions and methods for inhibiting pathogenic growth | |
US7323166B2 (en) | Lactic acid bacteria cultures that inhibit food-borne pathogens | |
CN1703146B (en) | Compositions and methods for inhibiting pathogenic growth | |
ES2426162T3 (en) | Compositions and methods to inhibit the growth of pathogens | |
US20160143317A1 (en) | Lactic acid bacterium as pet dietary supplement | |
US20160175369A1 (en) | Compositions and methods for reducing infection in poultry | |
WO2024153628A1 (en) | Probiotic strains capable of inhibiting fusobacterium necrophorum and improving gut barrier integrity | |
Rodriguez | Evaluation of the Use of Probiotics in Rearing Dairy Calves | |
POLLMANN | THERAPEUTIC AND NUTRITIONAL VALUE OF LACTIC CULTURES IN CONVENTIONAL AND GNOTOBIOTIC PIGS. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NUTRITION PHYSIOLOGY CORPORATION, OKLAHOMA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WARE, DOUGLAS R.;GARNER, BRYAN;REEL/FRAME:021049/0281;SIGNING DATES FROM 20060208 TO 20060210 |
|
AS | Assignment |
Owner name: MADISON CAPITAL FUNDING LLC, AS AGENT, ILLINOIS Free format text: SECURITY AGREEMENT;ASSIGNOR:NUTRITION PHYSIOLOGY COMPANY, LLC;REEL/FRAME:021561/0116 Effective date: 20080915 |
|
AS | Assignment |
Owner name: NUTRITION PHYSIOLOGY COMPANY, LLC, OKLAHOMA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NUTRITION PHYSIOLOGY CORPORATION;REEL/FRAME:021603/0775 Effective date: 20080915 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |